Unassociated Document
As
filed
with the Securities and Exchange Commission on June 9, 2005
File
No.
333-124712
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
AMENDMENT
NO. 1
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
HEALTHCARE
ACQUISITION CORP.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of
incorporation
or organization)
|
|
6770
(Primary
Standard Industrial
Classification
Code Number)
|
|
20-2726770
(I.R.S.
Employer
Identification
Number)
|
2116
Financial Center
666
Walnut Street
Des
Moines, Iowa 50309
(515)
244-5746
(Address,
including zip code, and telephone number, including
area
code, of registrant’s principal executive offices)
|
|
Matthew
P. Kinley
2116
Financial Center
666
Walnut Street
Des
Moines, Iowa 50309
(515)
244-5746
(Name,
address, including zip code, and telephone number, including area code, of
agent
for service)
Copies
to:
Stuart
Neuhauser, Esq.
Ellenoff
Grossman & Schole LLP
370
Lexington Avenue, 19th Floor
New
York, New York 10017
(212)
370-1300
|
|
|
|
Alan
Wovsaniker, Esq.
Steven
Skolnick, Esq.
Lowenstein
Sandler PC
65
Livingston Avenue
Roseland,
New Jersey 07068
(973)
597-2500
|
Approximate
date of commencement of proposed sale to the public: As soon as practicable
after the effective date of this registration statement.
If
any of
the securities being registered on this Form are to be offered on a delayed
or
continuous basis pursuant to Rule 415 under the Securities Act of 1933
check the following box. x
If
this
Form is filed to register additional securities for an offering pursuant to
Rule 462(b) under the Securities Act, please check the following box
and
list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. o
If
this
Form is a post-effective amendment filed pursuant to Rule 462(c) under
the
Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering. o
If
this
Form is a post-effective amendment filed pursuant to Rule 462(d) under
the
Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering. o
If
delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. x
Calculation
of Registration Fee
Title
of Each Class of
Security
to be Registered
|
|
Amount
to be
Registered
|
|
Proposed
Maximum
Offering
Price
Per
Unit (1)
|
|
Proposed
Maximum
Aggregate
Offering
Price
(1)
|
|
Amount
of
Registration
Fee
|
|
Units,
each consisting of one share of Common Stock, $.0001 par value,
and one
Warrant (2)
|
|
|
6,900,000
|
|
$
|
8.00
|
|
$
|
55,200,000
|
|
$
|
6,497
|
|
Shares
of Common Stock included as part of the Units
(2)
|
|
|
6,900,000
|
|
|
—
|
|
|
—
|
|
|
—
|
(3)
|
Warrants
included as part of the Units
(2)
|
|
|
6,900,000
|
|
|
|
|
|
—
|
|
|
—
|
(3)
|
Shares
of Common Stock underlying the Warrants included in the Units (4)
|
|
|
6,900,000
|
|
$
|
6.00
|
|
$
|
41,400,000
|
|
$
|
4,873
|
|
Representative’s
Unit Purchase Option
|
|
|
1
|
|
$
|
100
|
|
$
|
100
|
|
$
|
0
|
|
Units
underlying the Representative’s Unit Purchase Option (“Representative’s
Units”)(4)
|
|
|
300,000
|
|
$
|
10.00
|
|
$
|
3,000,000
|
|
$
|
353
|
|
Shares
of Common Stock included as part of the Representative’s Units(4)
|
|
|
300,000
|
|
|
—
|
|
|
—
|
|
|
—
|
(3)
|
Warrants
included as part of the Representative’s Units(4)
|
|
|
300,000
|
|
|
—
|
|
|
—
|
|
|
—
|
(3)
|
Shares
of Common Stock underlying the Warrants included in the Representative’s
Units(4)
|
|
|
300,000
|
|
$
|
7.50
|
|
$
|
2,250,000
|
|
$
|
265
|
|
Total
|
|
|
|
|
|
|
|
$
|
101,850,100
|
|
$
|
11,988
|
(5)
|
(1) |
Estimated solely for the purpose of calculating
the
registration fee. |
(2)
|
Includes
900,000 Units and 900,000 shares of Common Stock and 900,000 Warrants
underlying such Units which may be issued on exercise of a 45-day
option
granted to the Underwriters to cover over-allotments, if any.
|
(3) |
No fee pursuant to
Rule 457(g). |
(4)
|
Pursuant
to Rule 416, there are also being registered such indeterminable
additional securities as may be issued as a result of the anti-dilution
provisions contained in the Warrants.
|
The
registrant hereby amends this registration statement on such date or dates
as
may be necessary to delay its effective date until the registrant shall file
a
further amendment which specifically states that this registration statement
shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until the registration statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
Preliminary
Prospectus |
Subject
to Completion, June 9,
2005
|
The
information in this prospectus is not complete and may be changed. We may
not
sell these securities until the registration statement filed with the Securities
and Exchange Commission is effective. This prospectus is not an offer to
sell
these securities and it is not soliciting an offer to buy these securities
in
any state where the offer or sale is not permitted.
$48,000,000
HEALTHCARE
ACQUISITION CORP.
6,000,000
units
Healthcare
Acquisition Corp. is a blank check company recently formed for the purpose
of
acquiring, through a merger, capital stock exchange, asset acquisition or other
similar business combination, one or more domestic or international assets
or an
operating business in the healthcare industry. We
do not
have any specific merger, capital stock exchange, asset acquisition or other
business combination under consideration or contemplation and we have not,
nor
has anyone on our behalf, contacted any potential target business or had any
discussions, formal or otherwise, with respect to such a transaction.
This
is
an initial public offering of our securities. Each unit consists
of:
· |
one
share of our common stock; and
|
Each
warrant entitles the holder to purchase one share of our common stock at a
price
of $6.00. Each warrant will become exercisable on the later of our completion
of
a business combination or ______________,
2006
[one
year from the date of this prospectus],
and
will expire on ______________,
2009
[four
years from the date of this prospectus],
or
earlier upon redemption.
We
have
granted the underwriters a 45-day option to purchase up to 900,000 additional
units solely to cover over-allotments, if any (over and above the 6,000,000
units referred to above). The over-allotment will be used only to cover the
net
syndicate short position resulting from the initial distribution. We have also
agreed to sell to Maxim Group LLC, the representative of the underwriters,
for
$100, as additional compensation, an option to purchase up to a total of 300,000
units at $10.00 per unit, with the warrants issued as part of such units
exercisable at $7.50 per share. Otherwise, the units issuable upon exercise
of
this option are identical to those offered by this prospectus. The purchase
option and its underlying securities have been registered under the registration
statement of which this prospectus forms a part.
There
is
presently no public market for our units, common stock or warrants. We intend
to
apply to have our units quoted on the OTC Bulletin Board under the symbol
“_______”on
or
promptly after the date of this prospectus. Once the securities comprising
the
units begin separate trading, the common stock and warrants will be traded
on
the OTC Bulletin Board under the symbols “_______”and
“_______”,
respectively.
Investing
in our securities involves a high degree of risk. See “Risk Factors” beginning
on page 8 of this prospectus for a discussion of information that should be
considered in connection with an investment in our securities.
Neither
the Securities and Exchange Commission nor any state securities commission
has
approved or disapproved of these securities or determined if this prospectus
is
truthful or complete. Any representation to the contrary is a criminal offense.
|
|
|
|
|
offering
price
|
Underwriting
discount
and
commissions (1)
|
Proceeds,
before
expenses,
to us
|
Per
unit
|
$8.00
|
$0.64
|
$7.36
|
Total
|
$48,000,000
|
$3,840,000
|
$44,160,000
|
(1)
|
Includes
a non-accountable expense allowance in the amount of 1% of the gross
proceeds, or $0.08 per unit ($480,000 in total) payable to Maxim
Group
LLC, and also includes an additional underwriting discount in the
amount
of 1% of the gross proceeds, or $0.08 per unit ($480,000 in total),
payable to Maxim Group LLC (including any units sold to cover
overallotments), payable upon consummation of a business combination.
|
Of
the
net proceeds we receive from this offering, $42,960,000 ($7.16 per unit) will
be
deposited into a trust account at JP Morgan Chase NY Bank maintained by
Continental Stock Transfer & Trust Company, acting as trustee.
We
are
offering the units for sale on a firm-commitment basis. Maxim Group LLC, acting
as representative of the underwriters, expects to deliver our securities to
investors in the offering on or about ______________,
2005.
MAXIM
GROUP LLC
TABLE
OF CONTENTS
|
Page
|
Prospectus
Summary
|
1
|
Summary
Financial Data
|
7
|
Risk
Factors
|
8
|
Use
of Proceeds
|
23
|
Dilution
|
27
|
Capitalization
|
28
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
29
|
Proposed
Business
|
31
|
Management
|
42
|
Principal
Stockholders
|
46
|
Certain
Relationships and Related Transactions
|
48
|
Description
of Securities
|
50
|
Underwriting
|
55
|
Legal
Matters
|
60
|
Experts
|
60
|
Where
You Can Find Additional Information
|
60
|
Index
to Financial Statements
|
F-1
|
You
should rely only on the information contained or incorporated by reference
in
this prospectus. We have not authorized anyone to provide you with different
information. We are not making an offer of these securities in any jurisdiction
where the offer is not permitted.
PROSPECTUS
SUMMARY
This
summary highlights certain information appearing elsewhere in this prospectus.
For a more complete understanding of this offering, you should read the entire
prospectus carefully, including the risk factors and the financial statements.
Unless otherwise stated in this prospectus, references to “we,”“us” or “our
company” refer to Healthcare Acquisition Corp. The
term "public stockholders" means the holders of common stock sold as part of
the
units in this offering or in the open market, including any existing
stockholders to the extent that they purchase or acquire such shares.
Unless
we tell you otherwise, the information in this prospectus assumes that the
underwriters will not exercise their over-allotment option.
The
Company
We
are a
blank check company organized under the laws of the State of Delaware on April
25, 2005. We were formed to acquire, through a merger, capital stock exchange,
asset acquisition or other similar business combination, one or more domestic
or
international assets or an operating business in the healthcare industry. To
date, our efforts have been limited to organizational activities and we have
not
acquired any business operations. Further, we
do not
have any specific merger, capital stock exchange, asset acquisition or other
business combination under consideration or contemplation and we have not,
nor
has anyone on our behalf, contacted any potential target business or had any
discussions, formal or otherwise, with respect to such a transaction.
The
healthcare industry constitutes one of the largest segments of the United States
economy. According to the Centers for Medicare and Medicaid Services, or CMS,
healthcare expenditures have increased from $245.8 billion in 1980 to a
forecasted $1.9 trillion in 2005, representing a Compound Annual Growth Rate,
or
CAGR, of 9%. Further, in 2003, approximately 64% of total healthcare
expenditures were spent on the following categories: hospital care (31%),
physician and clinical services (23%) and prescription drugs (10%). In 2003,
healthcare expenditures totaled $1.7 trillion (or $5,800 per American) and
accounted for 15.3% of Gross Domestic Product, or GDP, which outpaced overall
economic growth by 3%. In the future, national health expenditures are projected
to reach $3.6 trillion by 2014, representing a CAGR of 7.4% over the next ten
years. Health spending is projected to reach 18.7% of GDP by 2014. We anticipate
the substantial growth in healthcare witnessed over the past 25 years should
continue going forward. Therefore, we believe there will be numerous acquisition
targets within the healthcare sector.
While
we
may seek to effect business combinations with more than one target business
in
the healthcare industry, our initial business combination must be for assets
or
with a target business whose fair market value is at least equal to 80% of
our
net assets at the time of such acquisition. Consequently, it is likely that
we
will have the ability to effect only a single business combination. As used
in
this prospectus, a “target business” shall include assets or an operating
business in the healthcare industry and a “business combination” shall mean the
acquisition by us of such assets or target business. We will not enter into
any
business combination with any affiliates of our initial stockholders, officers
or directors.
Our
officers and directors will not receive any compensation in this offering other
than reimbursement for out-of-pocket expenses incurred by them on our behalf,
which includes an aggregate of $175,000 in loans which they made to us in April,
2005. After the consummation of a business combination, if any, to the extent
they remain as officers of the resulting business, we anticipate that they
may
enter into employment agreements, the terms of which shall be negotiated and
which we expect to be comparable to employment agreements with other
similarly-situated companies in the healthcare industry. Further, after the
consummation of a business combination, if any, to the extent such persons
remain as directors of the resulting business, we anticipate that they will
receive compensation comparable to directors at other similarly-situated
companies in the healthcare industry.
In
addition, we have agreed to pay Equity Dynamics, Inc., an affiliated third
party
of which Mr. Pappajohn (our Chairman and Secretary) is the President and
principal stockholder, and Mr. Kinley (our President and Treasurer) is a Senior
Vice President, approximately $6,000 per month for office space and certain
additional general and administrative services. We have also agreed to pay
another affiliated third party, The Lan Group, of which Dr. Schaffer (our Chief
Executive Officer) is the sole owner, approximately $1,500 per month for office
space and certain additional general and administrative services.
Our
executive offices are located at 2116 Financial Center, 666 Walnut Street,
Des
Moines, Iowa 50309, and our telephone number at that location is (515) 244-5746.
Securities
offered:
|
6,000,000
units, at $8.00 per unit, each unit consisting of:
• one
share of common stock; and
• one
warrant
The
units will begin trading on or promptly after the date of this
prospectus.
Each of the common stock and warrants shall trade separately on
the
90th
day
after the date of this prospectus unless Maxim Group LLC determines
that
an earlier date is acceptable. Upon such separation, the units
will no
longer trade. In no event will Maxim Group LLC allow separate trading
of
the common stock and warrants until we file an audited balance
sheet
reflecting our receipt of the gross proceeds of this offering.
We will
file a Current Report on Form 8-K, including an audited balance
sheet,
upon the consummation of this offering, which is anticipated to
take place
three business days from the date of this prospectus. The audited
balance
sheet will include proceeds we receive from the exercise of the
over-allotment option if the over-allotment option is exercised
prior to
the filing of the Form 8-K.
|
Common
stock:
|
|
Number
outstanding before this offering
|
1,500,000
shares
|
Number
to be outstanding after this offering
|
7,500,000
shares
|
Warrants:
|
|
Number
outstanding before this offering
|
0
|
Number
to be outstanding after this offering
|
6,000,000
warrants
|
Exercisability
|
Each
warrant is exercisable for one share of common stock.
|
Exercise
price
|
$6.00
per share
|
Exercise
period
|
The
warrants will become exercisable on the
later of:
• the
completion of a business combination with a target business, or
• _________________,
2006 [one
year from the date of this prospectus]
The
warrants will expire at 5:00 p.m., New York City time, on ________________,
2009 [four
years from the date of this prospectus]
or earlier upon redemption.
|
Redemption
|
We
may redeem the outstanding warrants:
•
in
whole and not in part,
•
at
a price of $.01 per warrant at any time after the warrants
become
exercisable,
•
upon
a minimum of 30 days’ prior written notice of redemption, and
•
if,
and only if, the average closing sales price of our common
stock equals or
exceeds $11.50 per share for any 20 trading days within a 30
trading day
period ending three business days before we send the notice
of
redemption.
We
have established this last criterion to provide warrant holders
with a
premium to the initial warrant exercise price as well as a
degree of
liquidity to cushion the market reaction, if any, to our redemption
call.
If the foregoing conditions are satisfied and we call the warrants
for
redemption, each warrant holder shall then be entitled to exercise
his or
her warrant prior to the date scheduled for redemption, however,
there can
be no assurance that the price of the common stock will exceed
the call
trigger price or the warrant exercise price after the redemption
call is
made.
|
Management
Warrant Purchase:
|
John
Pappajohn, our chairman and secretary, or his designees, has
agreed to
purchase up to $1,000,000 of our warrants in the open market,
at a price
per warrant not to exceed $1.20, within three months of such
warrants
being separately tradeable. These warrants will not be sold
by Mr.
Pappajohn or his designees until the consummation of a business
combination. Maxim Group LLC has also agreed to purchase up
to $500,000 of
our warrants in the open market on similar terms; however,
Maxim Group LLC
may sell their warrants prior to the consummation of a business
combination.
|
Proposed
OTC Bulletin Board symbols for our:
Units:
Common
Stock:
Warrants:
|
“_____”
“_____”
“_____”
|
Offering
proceeds to be held in trust:
|
$42,960,000
of the proceeds of this offering ($7.16 per unit) will be
placed in a
trust account at JP Morgan Chase NY Bank maintained by Continental
Stock
Transfer & Trust Company, pursuant to an agreement to be signed
on the date of this prospectus. These proceeds will not be
released until
the earlier of the completion of a business combination or
our
liquidation. Therefore, unless and until a business combination
is
consummated, the proceeds held in the trust fund will not
be available for
our use for any expenses related to this offering or expenses
which we may
incur related to the investigation and selection of a target
business and
the negotiation of an agreement to acquire a target business.
These
expenses may be paid prior to a business combination only
from the net
proceeds of this offering not held in the trust fund (initially,
approximately $1,300,000 after the payment of the expenses
relating to
this offering). It
is possible that we could use a portion of the funds not
in the trust
account to make a deposit, down payment or fund a "no-shop"
provision with
respect to a particular proposed business combination. In
the event we
were ultimately required to forfeit such funds (whether as
a result of our
breach of the agreement relating to such payment or otherwise),
we may not
have a sufficient amount of working capital available outside
of the trust
account to pay expenses related to finding a suitable business
combination
without securing additional financing. If we were unable
to secure
additional financing, we would most likely fail to consummate
a business
combination in the allotted time and would be forced to
liquidate.
None
of the warrants may be exercised until after the consummation
of a
business combination and, thus, after the proceeds of the
trust fund have
been disbursed, the warrant exercise price will be paid directly
to us.
|
Stockholders
must approve business combination:
|
We
will seek stockholder approval before we effect any business
combination,
even if the nature of the acquisition would not ordinarily
require
stockholder approval under applicable state law. In connection
with the
vote required for any business combination, all of our existing
stockholders, including all of our officers and directors,
have agreed to
vote the shares of common stock owned by them immediately
before this
offering in accordance with the majority of the shares of
common stock
voted by the public stockholders. We will proceed with a
business
combination
only if a majority of the shares of common stock voted by
the public
stockholders are voted in favor of the business combination
and public
stockholders owning less than 20% of the shares sold in this
offering
exercise their conversion rights described below. Voting
against the business combination alone will not result in
conversion of a
stockholder's shares into a pro rata share of the trust fund.
Such
stockholder must have also exercised its conversion rights
described
below.
We
will not enter into any business combination with any affiliates
of our
initial stockholders, officers or directors.
|
Conversion
rights for stockholders voting to reject a business
combination:
|
Public
stockholders voting against a business combination will be
entitled to
convert their stock into a pro rata share of the trust fund,
including any
interest earned on their portion of the trust fund, if the
business
combination is approved and completed. Public
stockholders that convert their stock into their pro rata
share of the
trust fund will continue to have the right to exercise any
warrants they
may hold. Because the initial per share conversion price
is $7.16 per
share (plus any interest), which is lower than the $8.00
per unit price
paid in the offering and, which may be lower than the market
price of the
common stock on the date of the conversion, there may be
a disincentive on
the part of public stockholders to exercise their conversion
rights. The
term public stockholders means the holders of common stock
sold as part of
the units in this offering or in the open market, including
any existing
stockholders to the extent that they purchase or acquire
such shares.
|
Liquidation
if no business combination:
|
We
will dissolve and promptly distribute only to our public
stockholders the
amount in our trust fund plus any remaining net assets if
we do not effect
a business combination within 18 months after consummation
of this
offering (or within 24 months from the consummation of this
offering if a
letter of intent, agreement in principle or definitive agreement
has been
executed within 18 months after consummation of this offering
and the
business combination has not yet been consummated within
such 18 month
period). Our
existing stockholders have agreed to waive their respective
rights to
participate in any liquidation distribution occurring upon
our failure to
consummate a business combination, but only with respect
to those shares
of common stock acquired by them prior to this offering.
|
Escrow
of existing stockholders’ shares:
|
On
the date of this prospectus, all of our existing stockholders,
including
all of our officers and directors, will place the shares
they owned before
this offering into an escrow account maintained by Continental
Stock
Transfer & Trust Company, acting as escrow agent. Subject to
certain limited exceptions, such
as transfers to family members and trusts for estate planning
purposes and
upon death while remaining subject to the escrow agreement,
these shares will not be transferable during the escrow period
and will
not be released from escrow until ______________,
2008 [three
years from the date of this prospectus],
unless
we were to consummate a transaction after the consummation
of the initial
business combination which results in all of the stockholders
of the
combined entity having the right to exchange their shares
of common stock
for cash, securities or other property.
|
In
making
your decision on whether to invest in our securities, you should take into
account not only the backgrounds of our management team, but also the special
risks we face as a blank check company, as well as the fact that this offering
is not being conducted in compliance with Rule 419 promulgated under
the
Securities Act of 1933, as amended, and, therefore, you will not be entitled
to
protections normally afforded to investors in Rule 419 blank check
offerings. You should carefully consider these and the other risks set forth
in
the section entitled “Risk Factors” beginning on page 8 of this prospectus.
SUMMARY
FINANCIAL DATA
The
following table summarizes the relevant financial data for our business and
should be read with our financial statements, which are included in this
prospectus. We have not had any significant operations to date, so only balance
sheet data is presented.
|
|
April
30, 2005
|
|
|
|
Actual
|
|
As
Adjusted
|
|
Balance
Sheet Data:
|
|
|
|
|
|
Working
capital/(deficiency)
|
|
$
|
(90,753
|
)
|
$
|
44,282,500
|
|
Total
assets
|
|
|
253,253
|
|
|
44,282,500
|
|
Total
liabilities
|
|
|
230,753
|
|
|
—
|
|
Value
of common stock which may be converted to cash ($7.16 per share)
|
|
|
—
|
|
|
8,587,704
|
|
Stockholders’
equity
|
|
|
22,500
|
|
|
35,694,796
|
|
The
“as
adjusted” information gives effect to the sale of the units we are offering
including the application of the related gross proceeds and the payment of
the
estimated remaining costs from such sale.
The
working capital and total assets amounts include the $42,960,000 to be held
in
the trust fund, which will be available to us only upon the consummation of
a
business combination within the time period described in this prospectus. If
a
business combination is not so consummated, we will be dissolved and the
proceeds held in the trust fund will be distributed solely to our public
stockholders. The
term
public stockholders means the holders of common stock sold as part of the units
in this offering or in the open market, including any existing stockholders
to
the extent that they purchase or acquire such shares.
We
will
not proceed with a business combination if public stockholders owning 20% or
more of the shares sold in this offering vote against the business combination
and exercise their conversion rights. Accordingly, we may effect a business
combination if public stockholders owning up to approximately 19.99% of the
shares sold in this offering exercise their conversion rights. If this occurred,
we would be required to convert to cash up to approximately 19.99% of the
6,000,000 shares sold in this offering, or 1,199,400 shares of common stock,
at
an initial per-share conversion price of $7.16, without taking into account
interest earned on the trust fund. The actual per-share conversion price will
be
equal to:
· |
the
amount in the trust fund, including all accrued interest, as of two
business days prior to the proposed consummation of the business
combination,
|
· |
divided
by
the number of shares of common stock sold in the offering.
|
RISK
FACTORS
An
investment in our securities involves a high degree of risk. You should consider
carefully all of the material risks described below, together with the other
information contained in this prospectus before making a decision to invest
in
our units.
Risks
Associated With Our Potential Business
We
are a newly formed company with no operating history and, accordingly, you
will
not have any basis on which to evaluate our ability to achieve our business
objective.
We
are a
recently formed company with no operating results to date. Therefore, our
ability to begin operations is dependent upon obtaining financing through the
public offering of our securities. Since we do not have any operations or an
operating history, you will have no basis upon which to evaluate our ability
to
achieve our business objective, which is to acquire one or more domestic or
international assets or an operating business in the healthcare industry. We
have not conducted any discussions and we have no plans, arrangements or
understandings with any prospective acquisition candidates. We will not generate
any revenues or income (other than interest income on the proceeds of this
offering) until, at the earliest, after the consummation of a business
combination.
If
we are forced to liquidate before a business combination, our public
stockholders will receive less than $8.00 per share upon distribution of the
trust fund and our warrants will expire worthless.
If
we are
unable to complete a business combination and are forced to liquidate our
assets, the per-share liquidation will be less than $8.00 because of the
expenses of this offering, our general and administrative expenses and the
anticipated costs of seeking a business combination after this offering.
Furthermore, there will be no distribution with respect to our outstanding
warrants and, accordingly, the warrants will expire worthless if we liquidate
before the completion of a business combination. For a more complete discussion
of the effects on our stockholders if we are unable to complete a business
combination, see the section below entitled “Effecting a business
combination—Liquidation if no business combination.”
You
will not be entitled to protections normally afforded to investors of blank
check companies.
Since
the
net proceeds of this offering are intended to be used to complete a business
combination with a target business that has not been identified, we may be
deemed to be a “blank check” company under the United States securities laws.
However, since we will have net tangible assets in excess of $5,000,000 upon
the
consummation of this offering and will file a Current Report on Form 8-K
with the SEC upon consummation of this offering, including an audited balance
sheet demonstrating this fact, we are exempt from rules promulgated by the
SEC
to protect investors of blank check companies such as Rule 419.
Accordingly, investors will not be afforded the benefits or protections of
those
rules. Because we are not subject to Rule 419, our units will be
immediately tradable. For a more detailed comparison of our offering to
offerings under Rule 419, see the section entitled “Comparison to offerings
of blank check companies” below.
Because
there are numerous companies with a business plan similar to ours seeking to
effectuate a business combination, it may be more difficult for us to complete
a
business combination.
Based
upon publicly available information, approximately 20 similarly structured
blank
check companies have completed initial public offerings since August 2003 and
numerous others have filed registration statements. Of these companies, only
one
company has consummated a business combination, while three other companies
have
announced they have entered into a definitive agreement for a business
combination, but have not consummated such business combination. Accordingly,
there are approximately 20 blank check companies with more than
$650 million in trust
that are
seeking to carry out a business plan similar to our business plan. While some
of
those companies have specific industries that they must complete a business
combination in, a number of them may consummate a business combination in any
industry they choose. We may therefore be subject to competition from these
and
other companies seeking to consummate a business plan similar to ours which
will, as a result, increase demand for privately-held companies to combine
with
companies structured similarly to ours. Further, the fact that only one of
such
companies has completed a business combination and three of such companies
have
entered into a definitive agreement for a business combination may be an
indication that there are only a limited number of attractive target businesses
available to such entities or that many privately-held target businesses may
not
be inclined to enter into business combinations with publicly held blank check
companies like us. We cannot assure you that we will be able to successfully
compete for an attractive business combination. Additionally, because of this
competition, we cannot assure you that we will be able to effectuate a business
combination within the required time periods. If we are unable to find a
suitable target business within such time periods, we will be forced to
liquidate.
If
third parties bring claims against us, the proceeds held in trust could be
reduced and the per-share liquidation price received by stockholders will be
less than $7.16 per share.
Our
placing of funds in trust may not protect those funds from third party claims
against us. Although we will seek to have all vendors, prospective target
businesses or other entities we engage execute agreements with us waiving any
right, title, interest or claim of any kind in or to any monies held in the
trust account for the benefit of our public stockholders, there is no guarantee
that they will execute such agreements. Nor is there any guarantee that such
entities will agree to waive any claims they may have in the future as a result
of, or arising out of, any negotiations, contracts or agreements with us and
will not seek recourse against the trust account for any reason. Accordingly,
the proceeds held in trust could be subject to claims which could take priority
over the claims of our public stockholders and the per-share liquidation price
could be less than $7.16 per share held in the trust account, plus interest,
due
to claims of such
creditors. If we are unable to complete a business combination and are forced
to
liquidate, our chairman and executive officers will be personally liable under
certain circumstances (for example, if a vendor does not waive any rights or
claims to the trust account) to ensure that the proceeds in the trust fund
are
not reduced by the claims of various vendors or other entities that are owed
money by us for services rendered or products sold to us, to the extent
necessary to ensure that such claims do not reduce the amount in the trust
fund.
However, we cannot assure you that our executive officers will be able to
satisfy those obligations.
We
may issue shares of our capital stock or debt securities to complete a business
combination, which would reduce the equity interest of our stockholders and
likely cause a change in control of our ownership.
Our
certificate of incorporation authorizes the issuance of up to 100,000,000 shares
of common stock, par value $.0001 per share, and 1,000,000 shares of preferred
stock, par value $.0001 per share. Immediately after this offering (assuming
no
exercise of the underwriters’ over-allotment option), there will be 86,500,000
authorized but unissued shares of our common stock available for issuance (after
appropriate reservation for the issuance of shares upon full exercise of our
outstanding warrants) and all of the 1,000,000 shares of preferred stock
available for issuance. Although we have no commitments as of the date of this
offering to issue our securities, we may issue a substantial number of
additional shares of our common stock or preferred stock, or a combination
of
common and preferred stock, to complete a business combination. The issuance
of
additional shares of our common stock or any number of shares of our preferred
stock:
· |
may
significantly reduce the equity interest of investors in this offering;
|
· |
will
likely cause a change in control if a substantial number of our shares
of
common stock are issued, which may affect, among other things, our
ability
to use our net operating loss carry forwards, if any, and most likely
also
result in the resignation or removal of our present officers and
directors; and
|
· |
may
adversely affect prevailing market prices for our common stock.
|
Additionally,
the healthcare industry is capital intensive, traditionally using substantial
amounts of indebtedness to finance acquisitions, capital expenditures and
working capital needs. If we finance the purchase of assets or operations
through the issuance of debt securities, it could result in:
· |
default
and foreclosure on our assets if our operating revenues after a business
combination were insufficient to pay our debt obligations;
|
· |
acceleration
of our obligations to repay the indebtedness even if we have made
all
principal and interest payments when due if the debt security contained
covenants that required the maintenance of certain financial ratios
or
reserves and any such covenant were breached without a waiver or
renegotiation of that covenant;
|
· |
our
immediate payment of all principal and accrued interest, if any,
if the
debt security was payable on demand; and
|
· |
our
inability to obtain additional financing, if necessary, if the debt
security contained covenants restricting our ability to obtain additional
financing while such security was outstanding.
|
For
a
more complete discussion of the possible structure of a business combination,
see the section below entitled “Effecting a business combination—Selection of a
target business and structuring of a business combination.”
Our
ability to effect a business combination and to execute any potential business
plan afterwards will be totally dependent upon the efforts of our key personnel,
some of whom may join us following a business combination and whom we would
have
only a limited ability to evaluate.
Our
ability to effect a business combination will be totally dependent upon the
efforts of our key personnel. The future role of our key personnel following
a
business combination, however, cannot presently be fully ascertained. Although
we expect most of our management and other key personnel, particularly our
chairman of the board, vice chairman and president to each remain associated
with us following a business combination, we may employ other personnel
following the business combination. While we intend to closely scrutinize any
additional individuals we engage after a business combination, we cannot assure
you that our assessment of these individuals will prove to be correct.
Moreover,
our current management will only be able to remain with the combined company
after the consummation of a business combination if they are able to negotiate
the same as part of any such combination. If we acquired a target business
in an
all-cash transaction, it would be more likely that current members of management
would remain with us if they chose to do so. If a business combination were
structured as a merger whereby the stockholders of the target company were
to
control the combined company following a business combination, it may be less
likely that management would remain with the combined company unless it was
negotiated as part of the transaction via the acquisition agreement, an
employment agreement or other arrangement. In making the determination as to
whether current management should remain with us following the business
combination, management will analyze the experience and skill set of the target
business' management and negotiate as part of the business combination that
certain members of current management remain if it is believed that it is in
the
best interests of the combined company post-business combination. If management
negotiates to be retained post-business combination as a condition to any
potential business combination, such negotiations may result in a conflict
of
interest.
Our
officers and directors may allocate their time to other businesses thereby
causing conflicts of interest in their determination as to how much time to
devote to our affairs. This could have a negative impact on our ability to
consummate a business combination.
Our
officers and directors are not required to commit their full time to our
affairs, which may result in a conflict of interest in allocating their time
between our operations and other businesses. We do not intend to have any full
time employees prior to the consummation of a business combination. Each of
our
officers are engaged in several other business endeavors and are not obligated
to contribute any specific number of hours per week to our affairs. If our
officers’ other business affairs require them to devote more substantial amounts
of time to such affairs, it could limit their ability to devote time to our
affairs and could have a negative impact on our ability to consummate a business
combination. For a discussion of potential conflicts of interest that you should
be aware of, see the section below entitled “Management—Conflicts of Interest.”
We cannot assure you that these conflicts will be resolved in our favor.
Our
officers and directors are currently affiliated with entities engaged in
business activities similar to those intended to be conducted by us and
accordingly, may have conflicts of interest in determining which entity a
particular business opportunity should be presented to.
Our
officers and directors may in the future become affiliated with other entities,
including other “blank check” companies, engaged in business activities similar
to those intended to be conducted by us. Additionally, our officers and
directors may become aware of business opportunities which may be appropriate
for presentation to us as well as the other entities with which they are or
may
be affiliated. Further, certain of our officers and directors are currently
involved in other businesses that are similar to the business activities that
we
intend to conduct following a business combination. Due to these existing
affiliations, they have prior fiduciary obligations to present potential
business opportunities to those entities prior to presenting them to us which
could cause additional conflicts of interest. Accordingly, they have conflicts
of interest in determining to which entity a particular business opportunity
should be presented. For a complete discussion of our management’s business
affiliations and the potential conflicts of interest that you should be aware
of, see the sections below entitled “Management—Directors and Executive
Officers” and “Management—Conflicts of Interest.” We cannot assure you that
these conflicts will be resolved in our favor.
All
of our directors own shares of our securities which will not participate in
liquidation distributions and therefore they may have a conflict of interest
in
determining whether a particular target business is appropriate for a business
combination.
All
of
our directors own shares of common stock in our company which were issued prior
to this offering, but have waived their right to receive distributions with
respect to those shares upon our liquidation if we are unable to complete a
business combination. Additionally, our chairman, or his designees, has agreed
to purchase up to an aggregate of $1,000,000 of warrants on the open market
for
a price not to exceed $1.20 per warrant, once such warrants begin to trade
separately. These warrants will not be sold until the consummation of a business
combination. The shares and warrants owned by these directors will be worthless
if we do not consummate a business combination. The personal and financial
interests of these directors may influence their motivation in identifying
and
selecting a target business and completing a business combination in a timely
manner. Consequently, these directors’ discretion in identifying and selecting a
suitable target business may result in a conflict of interest when determining
whether the terms, conditions and timing of a particular business combination
are appropriate and in our stockholders’ best interest.
Our
existing stockholders will not receive reimbursement for any out-of-pocket
expenses incurred by them to the extent that such expenses exceed the amount
in
the trust fund unless the business combination is consummated and therefore
they
may have a conflict of interest.
Our
existing stockholders, will not receive reimbursement for any out-of-pocket
expenses incurred by them to the extent that such expenses exceed the amount
in
the trust fund unless the business combination is consummated. The financial
interest of such persons could influence their motivation in selecting a target
business and thus, there may be a conflict of interest when determining whether
a particular business combination is in the stockholders' best interest.
If
our common stock becomes subject to the SEC’s penny stock rules, broker-dealers
may experience difficulty in completing customer transactions and trading
activity in our securities may be adversely affected.
If
at any
time we have net tangible assets of $5,000,000 or less and our common stock
has
a market price per share of less than $5.00, transactions in our common stock
may be subject to the “penny stock” rules promulgated under the Securities
Exchange Act of 1934. Under these rules, broker-dealers who recommend such
securities to persons other than institutional accredited investors must:
· |
make
a special written suitability determination for the purchaser;
|
· |
receive
the purchaser’s written agreement to a transaction prior to sale;
|
· |
provide
the purchaser with risk disclosure documents which identify certain
risks
associated with investing in “penny stocks” and which describe the market
for these “penny stocks” as well as a purchaser’s legal remedies; and
|
· |
obtain
a signed and dated acknowledgment from the purchaser demonstrating
that
the purchaser has actually received the required risk disclosure
document
before a transaction in a “penny stock” can be completed.
|
If
our
common stock becomes subject to these rules, broker-dealers may find it
difficult to effectuate customer transactions and trading activity in our
securities may be adversely affected. As a result, the market price of our
securities may be depressed, and you may find it more difficult to sell our
securities.
It
is probable that we will only be able to complete one business combination,
which will cause us to be solely dependent on a single business.
The
net
proceeds from this offering will provide us with approximately $44,260,000
which
we may use to complete a business combination. Our initial business combination
must be with a business with a fair market value of at least 80% of our net
assets at the time of such acquisition. Consequently, it is probable that we
will have the ability to complete only a single business combination, although
this may entail the simultaneous acquisitions of several assets or closely
related operating businesses at the same time. Accordingly, the prospects for
our ability to effect our business strategy may be:
· |
solely
dependent upon the performance of a single business; or
|
· |
dependent
upon the development or market acceptance of a single or limited
number of
products, processes or services.
|
We
may be unable to obtain additional financing, if required, to complete a
business combination or to fund the operations and growth of the target
business, which could compel us to restructure the transaction or abandon a
particular business combination.
Although
we believe that the net proceeds of this offering will be sufficient to allow
us
to consummate a business combination, in as much as we have not yet identified
any prospective target business, we cannot ascertain the capital requirements
for any particular transaction. If the net proceeds of this offering prove
to be
insufficient, either because of the size of the business combination or the
depletion of the available net proceeds in search of a target business, or
because we become obligated to convert into cash a significant number of shares
from dissenting stockholders, we will be required to seek additional financing.
We cannot assure you that such financing would be available on acceptable terms,
if at all. To the extent that additional financing proves to be unavailable
when
needed to consummate a particular business combination, we would be compelled
to
restructure the transaction or abandon that particular business combination
and
seek an alternative target business candidate. In addition, if we consummate
a
business combination, we may require additional financing to fund the operations
or growth of the target business. The failure to secure additional financing
could have a material adverse effect on the continued development or growth
of
the target business. None of our officers, directors or stockholders is required
to provide any financing to us in connection with or after a business
combination.
Our
existing stockholders, including our officers and directors, control a
substantial interest in us and thus may influence certain actions requiring
stockholder vote.
Upon
consummation of our offering, our existing stockholders (including all of our
officers and directors) will collectively own 20% of our issued and outstanding
shares of common stock (assuming they do not purchase units in this offering).
Additionally, our chairman, or his designees, has agreed to purchase up to
an
aggregate of $1,000,000 of warrants on the open market for a price not to exceed
$1.20 per warrant, once such warrants begin to trade separately. These warrants
cannot be sold until after consummation of a business combination. None of
our
other existing stockholders, officers and directors has indicated to us that
they intend to purchase units in the offering or warrants on the open market.
Our
board
of directors is divided into two classes, each of which will generally serve
for
a term of two years with only one class of directors being elected in each
year.
It is unlikely that there will be an annual meeting of stockholders to elect
new
directors prior to the consummation of a business combination, in which case
all
of the current directors will continue in office at least until the consummation
of the business combination. If there is an annual meeting, as a consequence
of
our “staggered” board of directors, initially only a minority of the board of
directors will be considered for election and our existing stockholders, because
of their ownership position, will have considerable influence regarding the
outcome. Accordingly, our existing stockholders will continue to exert control
at least until the consummation of a business combination. In addition, our
existing stockholders and their affiliates and relatives are not prohibited
from
purchasing units in this offering or in the open market. If they do, we cannot
assure you that our existing stockholders will not have considerable influence
upon the vote in connection with a business combination.
The
difference between the public offering price per share of our common stock
and
the pro forma net tangible book value per share of our common stock after this
offering constitutes the dilution to you and the other investors in this
offering. The fact that our existing stockholders acquired their shares of
common stock at a nominal price has significantly contributed to this dilution.
Assuming the offering is completed, you and the other new investors will incur
an immediate and substantial dilution of approximately 29 % or $2.33 per share
(the difference between the pro forma net tangible book value per share of
$5.67, and the initial offering price of $8.00 per unit).
Our
outstanding warrants may have an adverse effect on the market price of common
stock and make it more difficult to effect a business combination.
In
connection with this offering, as part of the units (but not including any
overallotments issued to the underwriters), we will be issuing warrants to
purchase 6,000,000 shares of common stock. To the extent we issue shares of
common stock to effect a business combination, the potential for the issuance
of
substantial numbers of additional shares upon exercise of these warrants could
make us a less attractive acquisition vehicle in the eyes of a target business
as such securities, when exercised, will increase the number of issued and
outstanding shares of our common stock and reduce the value of the shares issued
to complete the business combination. Accordingly, our warrants may make it
more
difficult to effectuate a business combination or increase the cost of the
target business. Additionally, the sale, or even the possibility of sale, of
the
shares underlying the warrants could have an adverse effect on the market price
for our securities or on our ability to obtain future public financing. If
and
to the extent these warrants are exercised, you may experience dilution to
your
holdings.
If
our existing stockholders exercise their registration rights, it may have an
adverse effect on the market price our common stock and the existence of these
rights may make it more difficult to effect a business combination.
Our
existing stockholders are entitled to require us to register the resale of
their
shares of common stock at any time after the date on which their shares are
released from escrow, which, except in limited circumstances, will not be before
three years from the date of this prospectus. If our existing stockholders
exercise their registration rights with respect to all of their shares of common
stock, then there will be an additional 1,500,000 shares of common stock
eligible for trading in the public market. The presence of this additional
number of shares of common stock eligible for trading in the public market
may
have an adverse effect on the market price of our common stock. In addition,
the
existence of these rights may make it more difficult to effectuate a business
combination or increase the cost of the target business, as the stockholders
of
the target business may be discouraged from entering into a business combination
with us or will request a higher price for their securities as a result of
these
registration rights and the potential future effect their exercise may have
on
the trading market for our common stock.
If
you are not an institutional investor, you may purchase our securities in this
offering only if you reside within certain states and may engage in resale
transactions only in those states and a limited number of other jurisdictions.
We
have
applied to register our securities, or have obtained or will seek to obtain
an
exemption from registration, in Colorado, Delaware, the District of Columbia,
Florida, Hawaii, Illinois, Indiana, Maryland, New York, Rhode Island and
Wyoming. If you are not an “institutional investor,” you must be a resident of
these jurisdictions to purchase our securities in the offering. The definition
of an “institutional investor” varies from state to state but generally includes
financial institutions, broker-dealers,
banks, insurance companies and other qualified entities. Institutional investors
in every state except in Idaho and Oregon may purchase the units in this
offering pursuant to exemptions provided to such entities under the Blue Sky
laws of various states. However, in order to prevent resale transactions in
violation of states’ securities laws, you may engage in resale transactions only
in these states and in a limited number of other jurisdictions in which an
applicable exemption is available or an application has been filed and accepted.
This restriction on resale may limit your ability to resell the securities
purchased in this offering and may impact the price of our securities. For
a
more complete discussion of the state securities laws and registrations
affecting this offering, please see “Underwriting - State Blue Sky Information”
below.
We
intend to have our securities quoted on the OTC Bulletin Board, which will
limit
the liquidity and price of our securities more than if our securities were
quoted or listed on the Nasdaq Stock Market or a national exchange.
We
anticipate that our securities will be traded in the over-the-counter market.
It
is anticipated that they will be quoted on the OTC Bulletin Board, an
NASD-sponsored and operated inter-dealer automated quotation system for equity
securities not included in the Nasdaq Stock Market. Quotation of our securities
on the OTC Bulletin Board will limit the liquidity and price of our securities
more than if our securities were quoted or listed on The Nasdaq Stock Market
or
a national exchange.
The
representative of the underwriters in the offering has only limited experience
acting in such role.
Although
certain principals of Maxim Group LLC have extensive experience in the
securities industry, Maxim Group LLC itself was formed in October 2002 and
has
acted as the lead manager in only two firm commitment public offerings,
co-manager in two firm commitment public offerings and as a member of the
underwriting syndicate in forty underwritten public offerings. Since Maxim
Group
LLC has limited experience in underwriting firm commitment public offerings,
their lack of experience may adversely affect the public offering price of
our
units, common stock and warrants and the subsequent development, if any, of
a
trading market for our units, common stock and warrants.
If
we are deemed to be an investment company, we may be required to institute
burdensome compliance requirements and our activities may be restricted, which
may make it difficult for us to complete a business combination.
If
we are
deemed to be an investment company under the Investment Company Act of 1940,
our
activities may be restricted which, among other problems, may make it difficult
for us to complete a business combination. Such restrictions include:
· |
restrictions
on the nature of our investments; and
|
· |
restrictions
on the issuance of securities.
|
In
addition, we may have imposed upon us burdensome requirements, including:
· |
registration
as an investment company;
|
· |
adoption
of a specific form of corporate structure; and
|
· |
reporting,
record keeping, voting, proxy and disclosure requirements and other
rules
and regulations.
|
We
do not
believe that our anticipated principal activities will subject us to the
Investment Company Act of 1940. To this end, the proceeds held in trust may
only
be invested by the trust agent in “government securities” with specific maturity
dates. By restricting the investment of the proceeds to these instruments,
we
intend to meet the requirements for the exemption provided in Rule 3a-1
promulgated under the Investment Company Act of 1940. If we were deemed to
be
subject to the act, compliance with these additional regulatory burdens would
require additional expense that we have not allotted for.
All
of
our officers or directors own shares of our common stock, and no salary or
other
compensation will be paid to our officers or directors for services rendered
by
them on our behalf prior to or in connection with a business combination. We
believe that two members of our board of directors are “independent” as that
term is commonly used. However, under the policies of the North American
Securities Administrators Association, Inc., because our directors may
receive reimbursement for out-of-pocket expenses incurred by them in connection
with activities on our behalf such as identifying potential target businesses
and performing due diligence on suitable business combinations, state securities
administrators could take the position that such individuals are not
“independent.” If this were the case, they would take the position that we would
not have the benefit of independent directors examining the propriety of
expenses incurred on our behalf and subject to reimbursement. Additionally,
there is no limit on the amount of out-of-pocket expenses that could be incurred
and there will be no review of the reasonableness of the expenses by anyone
other than our board of directors, which would include persons who may seek
reimbursement, or a court of competent jurisdiction if such reimbursement is
challenged. Although we believe that all actions taken by our directors on
our
behalf will be in our best interests, whether or not two of them are deemed
to
be “independent,” we cannot assure you that this will actually be the case. If
actions are taken, or expenses are incurred that are actually not in our best
interests, it could have a material adverse effect on our business and
operations and the price of our stock held by the public stockholders.
Because
our initial stockholders’ initial equity investment was only $25,000, our
offering may be disallowed by state administrators that follow the North
American Securities Administrators Association, Inc. Statement of Policy
on
promotional or development stage companies.
Pursuant
to the Statement of Policy Regarding Promoter’s Equity Investment promulgated by
The North American Securities Administrators Association, Inc., an
international organization devoted to investor protection, any state
administrator may disallow an offering of a promotional or development stage
company if the initial equity investment by a company’s promoters does not equal
a certain percentage of the aggregate public offering price. Our promoters’
initial investment of $25,000 is less than the required $2,708,750 minimum
amount pursuant to this policy. Accordingly, a state administrator would have
the discretion to disallow our offering if it wanted to. We cannot assure you
that our offering would not be disallowed pursuant to this policy.
Since
we have not currently selected a prospective target business with which to
complete a business combination, investors in this offering are unable to
currently ascertain the merits or risks of the target business’ operations.
Since
we
have not yet identified a prospective target, investors in this offering have
no
current basis to evaluate the possible merits or risks of the target business’
operations. To the extent we complete a business combination with a financially
unstable company, an entity in its development stage and/or an entity subject
to
unknown or unmanageable liabilities, we may be affected by numerous risks
inherent in the business operations of those entities. Although our management
will endeavor to evaluate the risks inherent in a particular target business,
we
cannot assure you that we will properly ascertain or assess all of the
significant risk factors. We also cannot assure you that an investment in our
units will not ultimately prove to be less favorable to investors in this
offering than a direct investment, if an opportunity were available, in a target
business. For a more complete discussion of our selection of a target business,
see the section below entitled “Effecting a business combination—We have not
identified a target business.”
We
may acquire a domestic business with operations outside of the United States,
and may face certain economic and regulatory challenges that we may be unable
to
meet.
While
we
expect to acquire a business or assets in the United States, we may acquire
a
business or assets with operations outside the United States. There are certain
risks inherent in doing business in international markets, particularly in
the
healthcare industry, which is heavily regulated and controlled in many
jurisdictions outside the United States. These risks include:
|
•
|
less
developed healthcare infrastructures and generally higher costs;
|
|
|
|
|
•
|
difficulty
in obtaining the necessary healthcare regulatory approvals for any
potential expansion, and the possibility that any approvals that
may be
obtained would impose restrictions on the operation of the our business;
|
|
|
|
|
•
|
the
inability to manage and coordinate the healthcare regulatory requirements
of multiple jurisdictions that are constantly evolving and subject
to
unexpected change;
|
|
|
|
|
•
|
difficulties
in staffing and managing foreign operations;
|
|
|
|
|
•
|
fluctuations
in exchange rates;
|
|
|
|
|
•
|
reduced
or no protection for intellectual property rights; and
|
|
|
|
|
•
|
potentially
adverse tax consequences.
|
Our
inability to manage these risks effectively could adversely affect our proposed
business and limit our ability to expand our operations, which would have a
material adverse effect on the our business, financial condition and results
of
operations.
Risks
Associated with the Healthcare Industry
Even
if
we acquire domestic or international assets or operations, of which no
assurances can be given, our proposed business will be subject to numerous
risks, including the following:
Changes
in the healthcare industry are subject to various influences, each of which
may
affect our prospective business.
The
healthcare industry is subject to changing political, economic, and regulatory
influences. These factors affect the purchasing practices and operations of
healthcare organizations. Any changes in current healthcare financing and
reimbursement systems could cause us to make unplanned enhancements of our
prospective products or services, or result in delays or cancellations of
orders, or in the revocation of endorsement of our prospective products or
services by clients. Federal and state legislatures have periodically considered
programs to reform or amend the U.S. healthcare system at both the federal
and
state level. Such programs may increase governmental regulation or involvement
in healthcare, lower reimbursement rates, or otherwise change the environment
in
which healthcare industry participants operate. Healthcare industry participants
may respond by reducing their investments or postponing investment decisions,
including investments in our prospective products or services.
Many
healthcare industry participants are consolidating to create integrated
healthcare systems with greater market power. As the healthcare industry
consolidates, competition to provide products and services to industry
participants will become even more intense, as will the importance of
establishing a relationship with each industry participant. These industry
participants may try to use their market power to negotiate price reductions
for
our prospective products and services. If we were forced to reduce our prices,
our operating results could suffer if we could not achieve corresponding
reductions in our expenses.
Any
business we acquire will be subject to extensive government regulation. Any
changes to the laws and regulations governing our prospective business, or
the
interpretation and enforcement of those laws or regulations, could cause us
to
modify our operations and could negatively impact our operating results.
We
believe that our prospective business will be extensively regulated by the
federal government and any states in which we decide to operate. The laws and
regulations governing our operations, if any, are generally intended to benefit
and protect persons other than our stockholders. The government agencies
administering these laws and regulations have broad latitude to enforce them.
These laws and regulations along with the terms of any government contracts
we
may enter into would regulate how we do business, what products and services
we
could offer, and how we would interact with the public. These laws and
regulations, and their interpretations, are subject to frequent change. Changes
in existing laws or regulations, or their interpretations, or the enactment
of
new laws or regulations could reduce our revenue, if any, by:
|
·
|
imposing
additional capital requirements;
|
|
·
|
increasing
our liability;
|
|
·
|
increasing
our administrative and other costs;
|
|
·
|
increasing
or decreasing mandated benefits;
|
|
·
|
forcing
us to restructure our relationships with providers; or
|
|
·
|
requiring
us to implement additional or different programs and systems.
|
For
example, Congress enacted the Health Insurance Portability and Accountability
Act of 1996 which mandates that health plans enhance privacy protections for
member protected health information. This requires health plans to add, at
significant cost, new administrative, information and security systems to
prevent inappropriate release of protected member health information. Compliance
with this law is uncertain and has affected the revenue streams of entities
subject to it. Similarly, individual states periodically consider adding
operational requirements applicable to health plans, often without identifying
funding for these requirements. California recently required all health plans
to
make available to members independent medical review of their claims. Any
analogous requirements applied to our prospective products or services would
be
costly to implement and could affect our prospective revenues.
We
believe that our business, if any, will be subject to various routine and
non-routine governmental reviews, audits and investigation. Violation of the
laws governing our prospective operations, or changes in interpretations of
those laws, could result in the imposition of civil or criminal penalties,
the
cancellation of any contracts to provide products or services, the suspension
or
revocation of any licenses, and exclusion from participation in government
sponsored health programs, such as Medicaid and the State Children’s Health
Insurance Program. If we become subject to material fines or if other sanctions
or other corrective actions were imposed upon us, we might suffer a substantial
reduction in revenue, and might also lose one or more of our government
contracts and as a result lose significant numbers of members and amounts of
revenue.
The
current administration's issuance of new regulations, its review of the existing
Health Insurance Portability and Accountability Act of 1996 rules and other
newly published regulations, the states' ability to promulgate stricter rules,
and uncertainty regarding many aspects of the regulations may make compliance
with any new regulatory landscape difficult. In order to comply with any new
regulatory requirements, any prospective business we acquire may be required
to
employ additional or different programs and systems, the costs of which are
unknown to us at this time. Further, compliance with any such new regulations
may lead to additional costs that we have not yet identified. We do not know
whether, or the extent to which, we would be able to recover our costs of
complying with any new regulations. Any new regulations and the related
compliance costs could have a material adverse effect on our
business.
If
we are unable to attract qualified healthcare professionals at reasonable costs,
it could limit our ability to grow, increase our operating costs and negatively
impact our business.
We
may
rely significantly on our ability to attract and retain qualified healthcare
professionals who possess the skills, experience and licenses necessary to
meet
the certification requirements and the requirements of the hospitals, nursing
homes and other healthcare facilities with which we may work, as well as the
requirements of applicable state and federal governing bodies. We will compete
for qualified healthcare professionals with hospitals, nursing homes and other
healthcare organizations. Currently, for example, there is a shortage of
qualified nurses in most areas of the United States. Therefore, competition
for
nursing personnel is increasing, and nurses’ salaries and benefits have risen.
This may also occur with respect to other healthcare professionals on whom
our
business may become dependent.
Our
ability to attract and retain such qualified healthcare professionals will
depend on several factors, including our ability to provide attractive
assignments and competitive benefits and wages. We cannot assure you that we
will be successful in any of these areas. Because we may operate in a fixed
reimbursement environment, increases in the wages and benefits that we must
provide to attract and retain qualified healthcare professionals or increases
in
our reliance on contract or temporary healthcare professionals could negatively
affect our revenue. We may be unable to continue to increase the number of
qualified healthcare professionals that we recruit, decreasing the potential
for
growth of our business. Moreover, if we are unable to attract and retain
qualified healthcare professionals, we may have to limit the number of clients
for whom we can provide any of our prospective products or services.
We
may face substantial risks of litigation as a result of operating in the
healthcare industry. If we become subject to malpractice and related legal
claims, we could be required to pay significant damages, which may not be
covered by insurance.
Litigation
is a risk that each business contends with, and businesses operating in the
healthcare industry do so more than most. In recent years, medical product
companies have issued recalls of medical products, and physicians, hospitals
and
other health care providers have become subject to an increasing number of
legal
actions alleging malpractice, product liability or related legal theories.
Many
of these actions involve large monetary claims and significant defense costs.
We
intend to maintain liability insurance in amounts that we believe will be
appropriate for our prospective operations. We also intend to maintain business
interruption insurance and property damage insurance, as well as an additional
umbrella liability insurance policy. However, this insurance coverage may not
cover all claims against us. Insurance coverage may not continue to be available
at a cost allowing us to maintain adequate levels of insurance. If one or more
successful claims against us were not covered by or exceeded the coverage of
our
insurance, our financial condition could be adversely affected.
We
may be dependent on payments from Medicare and Medicaid. Changes in the rates
or
methods governing these payments for our prospective products or services,
or
delays in such payments, could adversely affect our prospective
revenue.
A
large
portion of our revenue may consist of payments from Medicare and Medicaid
programs. Because these are generally fixed payments, we would be at risk for
the cost of any products or services provided to our clients. We cannot assure
you that Medicare and Medicaid will continue to pay in the same manner or in
the
same amount that they currently do. Any reductions in amounts paid by government
programs for our prospective products or services or changes in methods or
regulations governing payments would adversely affect our potential revenue.
Additionally, delays in any such payments, whether as a result of disputes
or
for any other reason, would also adversely affect our potential
revenue.
If
our costs were to increase more rapidly than fixed payment adjustments we
receive from Medicare, Medicaid or other third-party payors for any of our
potential products
or services,
our revenue could be negatively impacted.
We
may
receive fixed payments for our prospective products or services based on the
level of service or care that we provide. Accordingly, our revenue may be
largely dependent on our ability to manage costs of providing any products
or
services and to maintain a client base. We may become susceptible to situations
where our clients may require more extensive and therefore more expensive
products or services than we may be able to profitably deliver. Although
Medicare, Medicaid and certain third-party payors currently provide for an
annual adjustment of various payment rates based on the increase or decrease
of
the medical care expenditure category of the Consumer Price Index, these
increases have historically been less than actual inflation. If these annual
adjustments were eliminated or reduced, or if our costs of providing our
products or services increased more than the annual adjustment, any revenue
stream we may generate would be negatively impacted.
We
may depend on payments from third-party payors, including managed care
organizations. If these payments are reduced, eliminated or delayed, our
prospective revenues could be adversely affected.
We
may be
dependent upon private sources of payment for any of our potential products
or
services. Any amounts that we may receive in payment for such products and
services may be adversely affected by market and cost factors as well as other
factors over which we have no control, including regulations and cost
containment and utilization decisions and reduced reimbursement schedules of
third-party payors. Any reductions in such payments, to the extent that we
could
not recoup them elsewhere, would have a material adverse effect on our
prospective business and results of operations. Additionally, delays in any
such
payments, whether as a result of disputes or for any other reason, would have
a
material adverse effect on our prospective business and results of
operations.
Medical
reviews and audits by governmental and private payors could result in material
payment recoupments and payment denials, which could negatively impact our
business.
Medicare
fiscal intermediaries and other payors may periodically conduct pre-payment
or
post-payment medical reviews or other audits of our prospective products or
services. In order to conduct these reviews, the payor would request
documentation from us and then review that documentation to determine compliance
with applicable rules and regulations, including the documentation of any
products or services that we might provide. We cannot predict whether medical
reviews or similar audits by federal or state agencies or commercial payors
of
such products or services will result in material recoupments or denials, which
could have a material adverse effect on our financial condition and results
of
operations.
If
the FDA or other state or foreign agencies impose regulations that affect our
potential products, our costs will increase.
The
development, testing, production and marketing of any of our potential products
that we may manufacture, market or sell following a business combination may
be
subject to regulation by the FDA as “devices” under the 1976 Medical Device
Amendments to the Federal Food, Drug and Cosmetic Act. Before a new medical
device, or a new use of, or claim for, an existing product can be marketed
in
the United States, it must first receive either 510(k) clearance or pre-market
approval from the FDA, unless an exemption applies. Either process can be
expensive and lengthy. The FDA's 510(k) clearance process usually takes from
three to twelve months, but it can take longer and is unpredictable. The process
of obtaining pre-market approval is much more costly and uncertain than the
510(k) clearance process and it generally takes from one to three years, or
even
longer, from the time the application is filed with the FDA.
In
the
United States, medical devices must be:
· |
manufactured
in registered and quality approved establishments by the FDA;
and
|
· |
produced
in accordance with the FDA Quality System Regulation ("QSR") for
medical
devices.
|
As
a
result, we may be required to comply with QSR requirements and if we fail to
comply with these requirements, we may need to find another company to
manufacture any such devices which could delay the shipment of our potential
product to our customers.
The
FDA
requires producers of medical devices to obtain FDA licensing prior to
commercialization in the United States. Testing, preparation of necessary
applications and the processing of those applications by the FDA is expensive
and time consuming. We do not know if the FDA would act favorably or quickly
in
making such reviews, and significant difficulties or costs may potentially
be
encountered by us in any efforts to obtain FDA licenses. The FDA may also place
conditions on licenses that could restrict commercial applications of such
products. Product approvals may be withdrawn if compliance with regulatory
standards is not maintained or if problems occur following initial marketing.
Delays imposed by the FDA licensing process may materially reduce the period
during which we have the exclusive right to commercialize any potential patented
products. We may make modifications to any potential devices and may make
additional modifications in the future that we may believe do not or will not
require additional clearances or approvals. If the FDA should disagree, and
require new clearances or approvals for the potential modifications, we may
be
required to recall and to stop marketing the potential modified devices. We
also
may be subject to Medical Device Reporting regulations, which would require
us
to report to the FDA if our products were to cause or contribute to a death
or
serious injury, or malfunction in a way that would likely cause or contribute
to
a death or serious injury. We cannot assure you that such problems will not
occur in the future.
Additionally,
our potential products may be subject to regulation by similar agencies in
other
states and foreign countries. Compliance with such laws or regulations,
including any new laws or regulations in connection any potential products
developed by us, might impose additional costs on us or marketing impediments
on
such products which could adversely affect our revenues and increase our
expenses. The FDA and state authorities have broad enforcement powers. Our
failure to comply with applicable regulatory requirements could result in
enforcement action by the FDA or state agencies, which may include any of the
following sanctions:
· |
warning
letters, fines, injunctions, consent decrees and civil
penalties;
|
· |
repair,
replacement, refunds, recall or seizure of our
products;
|
· |
operating
restrictions or partial suspension or total shutdown of
production;
|
· |
refusal
of requests for 510(k) clearance or premarket approval of new products,
new intended uses, or modifications to existing
products;
|
· |
withdrawal
of 510(k) clearance or premarket approvals previously granted;
and
|
If
any of
these events were to occur, it could harm our business.
The
FDA can impose civil and criminal enforcement actions and other penalties on
us
if we were to fail to comply with stringent FDA regulations.
Medical
device manufacturing facilities must maintain records, which are available
for
FDA inspectors documenting that the appropriate manufacturing procedures were
followed. Should we acquire such a facility as a result of a business
combination, the FDA would have authority to conduct inspections of such a
facility. Labeling and promotional activities are also subject to scrutiny
by
the FDA and, in certain instances, by the Federal Trade Commission. Any failure
by us to take satisfactory corrective action in response to an adverse
inspection or to comply with applicable FDA regulations could result in
enforcement action against us, including a public warning letter, a shutdown
of
manufacturing operations, a recall of our products, civil or criminal penalties
or other sanctions. From time to time, the FDA may modify such requirements,
imposing additional or different requirements which could require us to alter
our business methods which could potentially result in increased expenses.
We
estimate that the net proceeds of this offering will be as set forth in the
following table:
|
|
Allotment
Option
|
|
Over-Allotment
Option
Exercised
|
|
Gross
proceeds
|
|
|
48,000,000
|
|
|
55,200,000
|
|
Offering
expenses
|
|
|
|
|
|
|
|
Underwriting
discount (1)(2)
|
|
|
2,880,000
|
|
|
3,312,000
|
|
Underwriting
non-accountable expense allowance (3)
|
|
|
480,000
|
|
|
480,000
|
|
Legal
fees and expenses (including blue sky services and expenses)
|
|
|
200,000
|
|
|
200,000
|
|
Miscellaneous
expenses
|
|
|
11,327
|
|
|
11,327
|
|
Printing
and engraving expenses
|
|
|
50,000
|
|
|
50,000
|
|
Accounting
fees and expenses
|
|
|
25,000
|
|
|
25,000
|
|
SEC
registration fee
|
|
|
11,988
|
|
|
11,988
|
|
NASD
registration fee
|
|
|
10,685
|
|
|
10,685
|
|
Initial
trustee’s fee
|
|
|
1,000
|
|
|
1,000
|
|
D&O
Insurance
|
|
|
70,000
|
|
|
70,000
|
|
Net
proceeds
|
|
|
|
|
|
|
|
Held
in trust (2)
|
|
|
42,960,000
|
|
|
49,404,000
|
|
Not
held in trust
|
|
|
1,300,000
|
|
|
1,624,000
|
|
Total
net proceeds
|
|
|
44,260,000
|
|
|
51,028,000
|
|
Use
of net proceeds not held in trust
|
|
|
|
|
|
|
|
Legal,
accounting and other expenses attendant to the due diligence
investigations,
structuring
and negotiation of a business combination
|
|
|
200,000
|
|
|
200,000
|
|
Payment
for administrative services and support ($7,500 per month for 18
months)
|
|
|
135,000
|
|
|
135,000
|
|
Due
diligence of prospective target businesses
|
|
|
600,000
|
|
|
600,000
|
|
Legal
and accounting fees relating to SEC reporting obligations
|
|
|
50,000
|
|
|
50,000
|
|
Working
capital and reserves
|
|
|
315,000
|
|
|
639,000
|
|
Total
|
|
|
1,300,000
|
|
|
1,624,000
|
|
(1)
|
Consists
of an underwriting discount of 6% of the gross proceeds of this Offering
(including any units sold to cover overallotments).
|
(2)
|
Upon
consummation of a business combination, Maxim Group LLC will be paid
an
additional underwriting discount in the amount of 1% of the gross
proceeds
of this Offering (including any units sold to cover overallotments)
out of
the funds held in trust.
|
(3)
|
The
1% non-accountable expense allowance is not payable with respect
to the
units sold upon exercise of the underwriters’ over-allotment option.
|
$42,960,000,
or $49,404,000 if the underwriters’ over-allotment option is exercised in full,
of the net proceeds will be placed in a trust account at JP Morgan Chase NY
Bank
maintained by Continental Stock Transfer & Trust Company, New York, New
York, as trustee. The proceeds will not be released from the trust fund until
the earlier of the completion of a business combination or our liquidation.
The
proceeds held in the trust fund may be used as consideration to pay the sellers
of a target business with which we ultimately complete a business combination.
Any amounts not paid as consideration to the sellers of the target business
may
be used to finance operations of the target business or to effect other
acquisitions, as determined by our board of directors at that time.
We
have
agreed to pay Equity Dynamics, Inc., an affiliated third party of which Mr.
Pappajohn is the President and principal stockholder, and Mr. Kinley a Senior
Vice President, approximately $6,000 per month for office space and certain
additional general and administrative services. We have also agreed to pay
another affiliated third party, The Lan Group, of which Dr. Schaffer is the
sole
owner, approximately $1,500 per month for office space and certain additional
general and administrative services.
John
Pappajohn, our chairman and secretary, or his designees, has agreed to purchase
up to $1,000,000 of our warrants in the open market, at a price per warrant
not
to exceed $1.20, within three months of such warrants being separately
tradeable. These warrants will not be sold by Mr. Pappajohn or his designees
until the consummation of a business combination. Maxim Group LLC has also
agreed to purchase up to $500,000 of our warrants in the open market on similar
terms; however, Maxim Group LLC may sell their warrants prior to the
consummation of a business combination.
Prior
to
the closing of a business combination, we have agreed to obtain keyman life
insurance in the amount of $3,000,000 in the aggregate on the lives of certain
members of our management for a three year period. Based on current estimates,
the premium for such life insurance policies, of which we will be the sole
beneficiary, is expected to be approximately $5,000 per year.
We
intend
to use the excess working capital (approximately $315,000) being
held in reserve in the event due diligence, legal, accounting and other expenses
of structuring and negotiating business combinations exceed our estimates,
as
well as for reimbursement of any out-of-pocket expenses incurred by our existing
stockholders in connection with activities on our behalf as described below.
We
expect
that due diligence of prospective target businesses will be performed by some
or
all of our officers and directors and may include engaging market research
firms
and/or third party consultants. Our officers and directors will not receive
any
compensation for their due diligence of prospective target businesses, but
would
be reimbursed for any out-of-pocket expenses (such as travel expenses) incurred
in connection with such due diligence activities. We
believe that the excess working capital will be sufficient to cover the
foregoing expenses and reimbursement costs.
It
is
also possible that we could use a portion of such excess working capital to
make
a deposit, down payment or fund a "no-shop" provision with respect to a
particular proposed business combination, although we do not have any current
intention to do so. In the event that we were ultimately required to forfeit
such funds (whether as a result of our breach of the agreement relating to
such
payment or otherwise), we may not have a sufficient amount of working capital
available outside of the trust account to conduct due diligence and pay other
expenses related to finding another suitable business combination without
securing additional financing. Thus, if we were unable to secure additional
financing, we would most likely fail to consummate a business combination in
the
allotted time and would be forced to liquidate.
To
the
extent that our capital stock is used in whole or in part as consideration
to
effect a business combination, the proceeds held in the trust fund as well
as
any other net proceeds not expended will be used to finance the operations
of
the target business.
As
of the
date of this prospectus, Mr. Pappajohn, Dr. Schaffer and Mr. Kinley have loaned
us a total of $175,000 which was used to pay a portion of the expenses of this
offering, such as SEC registration fees, NASD registration fees and legal and
accounting fees and expenses. These loans will be payable without interest
on
the earlier of April 28, 2006 or the consummation of this offering. The loans
will be repaid out of the net proceeds of this offering not being placed in
trust.
The
net
proceeds of this offering not held in the trust fund and not immediately
required for the purposes set forth above will be invested only in United States
“government securities,” defined as any Treasury Bill issued by the United
States having a maturity of one hundred and eighty days or less so that we
are
not deemed to be an investment company under the Investment Company Act. The
interest income derived from investment of these net proceeds during this period
will be used to defray our general and administrative expenses, as well as
costs
relating to compliance with securities laws and regulations, including
associated professional fees, until a business combination is completed. We
believe that, upon consummation of this offering, we will have sufficient
available funds to operate for at least the next 24 months, assuming that a
business combination is not consummated during that time.
Other
than the $7,500 aggregate per month general and administrative service fees
described above, no
compensation of any kind (including finder’s and consulting fees) will be paid
to any of our existing stockholders, or any of their affiliates, for services
rendered to us prior to or in connection with the consummation of the business
combination. However, our existing stockholders will receive reimbursement
for
any out-of-pocket expenses incurred by them in connection with activities on
our
behalf, such as identifying potential target businesses and performing due
diligence on suitable business combinations. After the consummation of a
business combination, if any, to the extent our management remains as officers
of the resulting business, we anticipate that they may enter into employment
agreements, the terms of which shall be negotiated and which we expect to be
comparable to employment agreements with other similarly-situated companies
in
the healthcare industry. Further, after the consummation of a business
combination, if any, to the extent our directors remain as directors of the
resulting business, we anticipate that they will receive compensation comparable
to directors at other similarly-situated companies in the healthcare industry.
A
public
stockholder will be entitled to receive funds from the trust fund (including
interest earned on his, her or its portion of the trust fund) only in the event
of our liquidation upon our failure to complete a business combination or if
that public stockholder were to seek to convert such shares into cash in
connection with a business combination which the public stockholder voted
against and which we actually consummate. In no other circumstances will a
public stockholder have any right or interest of any kind to or in the trust
fund. The
term
public stockholders means the holders of common stock sold as part of the units
in this offering or in the open market, including any existing stockholders
to
the extent that they purchase or acquire such shares.
DILUTION
The
difference between the public offering price per share of common stock, assuming
no value is attributed to the warrants included in the units, and the pro forma
net tangible book value per share of our common stock after this offering
constitutes the dilution to investors in this offering. Net tangible book value
per share is determined by dividing our net tangible book value, which is our
total tangible assets less total liabilities (including the value of common
stock which may be converted into cash if voted against the business
combination), by the number of outstanding shares of our common stock.
At
April
30, 2005, our net tangible book value was a deficiency of $(90,753), or
approximately $(0.06) per share of common stock. After giving effect to the
sale
of 6,000,000 shares of common stock included in the units, and the deduction
of
underwriting discounts and estimated expenses of this offering, our pro forma
net tangible book value (as decreased by the value of 1,199,400 shares of common
stock which may be converted into cash) at April 30, 2005 would have been
$35,694,796 or $5.67 per share, representing an immediate increase in net
tangible book value of $5.73 per share to the existing stockholders and an
immediate dilution of $2.33 per share or 29% to new investors not exercising
their conversion rights.
The
following table illustrates the dilution to the new investors on a per-share
basis, assuming no value is attributed to the warrants included in the units:
Public
offering price
|
|
|
8.00
|
|
Net
tangible book value before this offering
|
|
|
(0.06
|
)
|
Increase
attributable to new investors
|
|
|
5.73
|
|
Pro
forma net tangible book value after this offering
|
|
$
|
5.67
|
|
Dilution
to new investors
|
|
$
|
2.33
|
|
Our
pro
forma net tangible book value after this offering has been reduced by
approximately $8,587,704 because if we effect a business combination, the
conversion rights to the public stockholders may result in the conversion into
cash of up to approximately 19.99% of the aggregate number of the shares sold
in
this offering at a per-share conversion price equal to the amount in the trust
fund calculated as of two business days prior to the consummation of the
proposed business combination, inclusive of any interest, divided by the number
of shares sold in this offering.
The
following table sets forth information with respect to our existing stockholders
and the new investors:
|
|
Shares
Purchased
|
|
Total
Consideration
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average
Price
Per
Share
|
|
|
|
Number
|
|
Percentage
|
|
Amount
|
|
Percentage
|
|
|
|
Existing
stockholders
|
|
|
1,500,000
|
|
|
20.0
|
%
|
$
|
25,000
|
|
|
0.001
|
%
|
$
|
0.0167
|
|
New
investors (1)
|
|
|
6,000,000
|
|
|
80.0
|
%
|
$
|
48,000,000
|
|
|
99.999
|
%
|
$
|
8.00
|
|
|
|
|
7,500,000
|
|
|
100.0
|
%
|
$
|
48,025,000
|
|
|
100
|
%
|
|
|
|
(1) |
Assumes
the sale of 6,000,000 units in this offering, but not the exercise
of
6,000,000 warrants to purchase
shares of our common stock sold as part of such
units.
|
The
following table sets forth our capitalization at April 30, 2005 and as adjusted
to give effect to the sale of our units and the application of the estimated
net
proceeds derived from the sale of our units:
|
|
|
April
30, 2005
|
|
|
|
|
Actual
|
|
|
As
Adjusted
|
|
Notes
payable, existing stockholders (1)
|
|
$
|
175,000
|
|
|
—
|
|
Common
stock, $.0001 par value, -0- and 1,199,400 shares which are subject
to
possible conversion, shares at conversion value (2)
|
|
$
|
—
|
|
$
|
8,587,704
|
|
Stockholders’
equity:
|
|
|
|
|
|
|
|
Preferred
stock, $.0001 par value, 1,000,000 shares authorized; none issued
or
outstanding
|
|
$
|
—
|
|
|
—
|
|
Common
stock, $.0001 par value, 100,000,000 shares authorized; 1,500,000
shares
issued and outstanding; 6,300,600 shares issued and outstanding
(excluding
1,199,400 shares subject to possible conversion), as adjusted
|
|
$
|
150
|
|
$
|
630
|
|
Additional
paid-in capital
|
|
$
|
24,850
|
|
$
|
35,696,666
|
|
Deficit
accumulated during the development stage
|
|
$
|
(2,500
|
)
|
$
|
(2,500
|
)
|
Total
stockholders’ equity
|
|
$
|
22,500
|
|
$
|
35,694,796
|
|
Total
capitalization
|
|
$
|
197,500
|
|
$
|
44,282,500
|
|
(1)
Notes
payable, existing stockholders, are payable on the earlier of April 28, 2006
or
the consummation of this offering.
(2) If
we
consummate a business combination, the conversion rights afforded to our public
stockholders may result in the conversion into cash (approximately $8,587,704)
of up to approximately 19.99% of the aggregate number of shares (approximately
1,199,400 shares) sold in this offering at a per-share conversion price equal
to
the amount in the trust fund ($7.16 per share), inclusive of any interest
thereon, as of two business days prior to the proposed consummation of a
business combination divided by the number of shares sold in this offering.
We
were
formed on April 25, 2005, to serve as a vehicle to acquire one or more domestic
or international assets or an operating business in the healthcare industry,
through a merger, capital stock exchange, asset acquisition or other similar
business combination. We intend to utilize cash derived from the proceeds of
this offering, our capital stock, debt or a combination of cash, capital stock
and debt, in effecting a business combination. The issuance of additional shares
of our capital stock:
· |
may
significantly reduce the equity interest of our stockholders;
|
· |
will
likely cause a change in control if a substantial number of our shares
of
common stock are issued, which may affect, among other things, our
ability
to use our net operating loss carry forwards, if any, and may also
result
in the resignation or removal of one or more of our present officers
and
directors; and
|
· |
may
adversely affect prevailing market prices for our common stock.
|
Similarly,
if we issued debt securities, it could result in:
· |
default
and foreclosure on our assets if our operating revenues after a business
combination were insufficient to pay our debt obligations;
|
· |
acceleration
of our obligations to repay the indebtedness even if we have made
all
principal and interest payments when due if the debt security contained
covenants that required the maintenance of certain financial ratios
or
reserves and any such covenant were breached without a waiver or
renegotiation of that covenant;
|
· |
our
immediate payment of all principal and accrued interest, if any,
if the
debt security was payable on demand; and
|
· |
our
inability to obtain additional financing, if necessary, if the debt
security contained covenants restricting our ability to obtain additional
financing while such security was outstanding.
|
We
have
neither engaged in any operations nor generated any revenues to date. Our entire
activity since inception has been to prepare for our proposed fundraising
through an offering of our equity securities.
We
estimate that the net proceeds from the sale of the units, after deducting
offering expenses of approximately $860,000, including $480,000 evidencing
the
underwriters’ non-accountable expense allowance of 1% of the gross proceeds, and
underwriting discounts of approximately $2,880,000 (or $3,312,000 if the
underwriters’ over-allotment option is exercised in full), will be approximately
$44,260,000 (or $51,028,000 if the underwriters’ over-allotment option is
exercised in full). Of this amount, $42,960,000, or $49,404,000 if the
underwriters’ over-allotment option is exercised in full, will be held in trust
and the remaining $1,300,000 (or $1,624,000 if the underwriters’ over-allotment
option is exercised in full) will not be held in trust. We will use
substantially all of the net proceeds of this offering to acquire a target
business, including identifying and evaluating prospective acquisition
candidates, selecting the target business, and structuring, negotiating and
consummating the business combination. To the extent that our capital stock
is
used in whole or in part as consideration to effect a business combination,
the
proceeds held in the trust fund as well as any other net proceeds not expended
will be used to finance the operations of the target business. We believe that,
upon consummation of this offering, the funds available to us outside of the
trust fund will be sufficient to allow us to operate for at least the next
24 months, assuming that a business combination is not consummated during
that time. Over this time period, we anticipate approximately $200,000 of
expenses for legal, accounting and other expenses attendant to the due diligence
investigations, structuring and negotiating of a business combination, $135,000
for administrative services and support payable to affiliated third parties
(up
to $7500 per month for 18
months), $600,000 of expenses for the due diligence and investigation of a
target business, $50,000 of expenses in legal and accounting fees relating
to
our SEC reporting obligations and $315,000 for general working capital that
will
be used for miscellaneous expenses and reserves. We do not believe we will
need
to raise additional funds following this offering in order to meet the
expenditures required for operating our business. However, we may need to raise
additional funds through a private offering of debt or equity securities if
such
funds are required to consummate a business combination that is presented to
us.
We would only consummate such a fund raising simultaneously with the
consummation of a business combination.
As
of the
date of this prospectus, Mr. Pappajohn, Dr. Schaffer and Mr. Kinley have loaned
us a total of $175,000 which was used to pay a portion of the expenses of this
offering, such as SEC registration fees, NASD registration fees and legal and
accounting fees and expenses. These loans will be payable without interest
on
the earlier of April 28, 2006 or the consummation of this offering. The loans
will be repaid out of the net proceeds of this offering not being placed in
trust.
PROPOSED
BUSINESS
Introduction
We
are a
blank check company organized under the laws of the State of Delaware on April
25, 2005 and formed to serve as a vehicle for the acquisition of one or more
domestic or international assets or an operating business in the healthcare
industry. We
do not
have any specific merger, capital stock exchange, asset acquisition or other
business combination under consideration or contemplation and we have not,
nor
has anyone on our behalf, contacted any potential target business or had any
discussions, formal or otherwise, with respect to such a transaction.
Overview
The
healthcare industry constitutes one of the largest segments of the United States
economy. According to the Centers for Medicare and Medicaid Services, or CMS,
healthcare expenditures have increased from $245.8 billion in 1980 to a
forecasted $1.9 trillion in 2005, representing a Compound Annual Growth Rate,
or
CAGR, of 9%. Further, in 2003, approximately 64% of total healthcare
expenditures were spent on the following categories: hospital care (31%),
physician and clinical services (23%) and prescription drugs (10%). In 2003,
healthcare expenditures totaled $1.7 trillion (or $5,800 per American) and
accounted for 15.3% of Gross Domestic Product, or GDP, which outpaced overall
economic growth by 3%. In the future, national health expenditures are projected
to reach $3.6 trillion by 2014, representing a CAGR of 7.4% over the next ten
years. Health spending is projected to reach 18.7% of GDP by 2014.
Funding
for healthcare comes from public and private sources. Medicaid and Medicare
programs were created in the mid 1960’s. Medicare focuses on elderly coverage
(over 65 years old) and the disabled of any age. Medicaid provides coverage
for
the poor and indigent population and is jointly funded by the Federal and State
governments. In 2002, according to CMS, roughly 34% of healthcare payments
came
from Medicaid and Medicare. Private health insurance supports roughly 35% of
total costs. As healthcare costs rise, the private sector is responding by
shifting more of the cost of healthcare to employees by paying a smaller percent
of healthcare premiums. The employee, usually in the form of a payroll
deduction, must pay the amount of the premium not funded by the employer.
However, according to the U.S. Census Bureau, approximately 40 million Americans
were uninsured in 2003.
Our
management believes that, as a result of continued growth, there will be
numerous acquisition targets within the healthcare sector. Our management
believes that this growth will be driven by the following factors:
· |
Expanding
and Aging Population.
According
to U.S. Census Bureau estimates, in 2005 the American population
is
approximately 296 million and growing. Simultaneously, we are witnessing
the “graying of America”, whereby the elderly population is increasing
more rapidly than the rest of the population and represents the largest
users of healthcare services. According to the U.S. Census Bureau,
approximately 12% of the U.S. population was over-65 in 2003 and
was
forecasted to account for roughly 20% of the population by 2030.
By 2010,
the number of people in the United States between the ages of 40
and 60 is
expected to grow from roughly 58 million to more than 64 million.
|
· |
Evolving
Medical Treatments.
Advances in technology have favorably impacted the development of
new
medical devices and treatments/therapies. The products are generally
more
effective and easier-to-use. Some of these breakthroughs have reduced
hospital stays, costs and recovery periods. The continued advancement
of
technological breakthroughs should continue to boost services administered
by healthcare providers.
|
· |
Increased
Consumer Awareness.
In
recent years, the publicity associated with new technological advances
and
new medical therapies has increased the number of patients visiting
healthcare professionals to seek treatment for new and innovative
therapies. Simultaneously, consumers have become more vocal due to
rising
costs and reduced access to physicians. Lastly, the rise in cosmetic
procedures has emerged as one of the fastest growing healthcare segments.
Since many cosmetic procedures require out-of-pocket expenditures,
this
rise may reflect a growing willingness by consumers to pay for certain
procedures out of their discretionary funds. We believe that more
active
and aware consumers will continue to stimulate a wide variety of
healthcare segments.
|
· |
Access
to Capital. The
venture capital community has traditionally embraced healthcare companies.
Capital investments have allowed entities to grow and expand via
consolidation or organic growth. Therefore, we believe there are
many
mature companies that may potentially serve as platforms for future
acquisitions and growth. According to Dow Jones VentureSource, 2,142
healthcare companies raised venture capital financing rounds from
2001-2004. In that time period, 66 venture-backed healthcare companies
completed initial public offerings and 194 venture-backed healthcare
companies were acquired via merger and
acquisition.
|
Although
we may consider a target business in any segment of the healthcare industry,
we
intend to concentrate our search for an acquisition candidate in the following
segments:
· |
healthcare
information technology;
|
· |
healthcare
facilities; and
|
· |
medical
devices and products.
|
Our
Management Team
Mr.
Pappajohn, our chairman and secretary, has been an active private equity
investor in healthcare companies for more than 30 years and has served as a
director of more than 40 public companies. Mr. Pappajohn has been a founder
in
several public healthcare companies such as Caremark Rx, Inc., Quantum Health
Resources and Radiologix, Inc. Mr. Pappajohn and Dr. Schaffer, our vice chairman
and chief executive officer, have worked together for more than fifteen years
on
a variety of healthcare companies and have co-founded Allion Healthcare, Inc,
Patient Infosystems, Inc. and Radiologix all of which are public companies.
In
addition, Mr. Pappajohn and Dr. Schaffer have worked together on many private
healthcare companies, such as Logisticare, Inc. and Source Medical
Corporation.
Dr.
Schaffer serves as a director of Allion Healthcare and Patient InfoSystems.
He
has served as chairman of several healthcare companies, including Radiologix
when it was private. He has been an active co-investor and co-founder of
companies with Mr. Pappajohn for more than fifteen years. Dr. Schaffer has
also
served as a director on many healthcare boards, including several health systems
and more than ten healthcare services and technology companies. Dr. Schaffer
is
also currently a Clinical Professor of Radiology at Weill Cornell Medical
College.
Mr.
Kinley, our president and treasurer, has been involved in the financing and
development of more than twenty companies with Mr. Pappajohn in the past ten
years. Mr. Kinley has worked with Dr. Schaffer for more than ten years on
healthcare services and technology companies. Mr. Kinley has also held various
positions at KPMG Peat Marwick, working on tax, audit and merger and acquisition
issues.
Effecting
a Business Combination
General
We
are
not presently engaged in, and we will not engage in, any substantive commercial
business for an indefinite period of time following this offering. We intend
to
utilize cash derived from the proceeds of this offering, our capital stock,
debt
or a combination of these in effecting a business combination. Although
substantially all of the net proceeds of this offering are intended to be
generally applied toward effecting a business combination as described in this
prospectus, the proceeds are not otherwise being designated for any more
specific purposes. Accordingly, prospective investors will invest in us without
an opportunity to evaluate the specific merits or risks of any one or more
business combinations. A business combination may involve the acquisition of,
or
merger with, a company which does not need substantial additional capital but
which desires to establish a public trading market for its shares, while
avoiding what it may deem to be adverse consequences of undertaking a public
offering itself. These include time delays, significant expense, loss of voting
control and compliance with various Federal and state securities laws. In the
alternative, we may seek to consummate a business combination with a company
that may be financially unstable or in its early stages of development or
growth. While we may seek to effect business combinations with more than one
target business, we will probably have the ability, as a result of our limited
resources, to effect only a single business combination.
We
have not identified a target business
To
date,
we
do not
have any specific merger, capital stock exchange, asset acquisition or other
business combination under consideration or contemplation and we have not,
nor
has anyone on our behalf, contacted any potential target business or had any
discussions, formal or otherwise, with respect to such a
transaction.
Subject
to the limitations that a target business have a fair market value of at least
80% of our net assets at the time of the acquisition, as described below in
more
detail, we will have virtually unrestricted flexibility in identifying and
selecting a prospective acquisition candidate. Accordingly, there is no basis
for investors in this offering to evaluate the possible merits or risks of
the
target business with which we may ultimately complete a business combination.
To
the extent we effect a business combination with a financially unstable company
or an entity in its early stage of development or growth, including entities
without established records of sales or earnings, we may be affected by numerous
risks inherent in the business and operations of financially unstable and early
stage or potential emerging growth companies. Although our management will
endeavor to evaluate the risks inherent in a particular target business, we
cannot assure you that we will properly ascertain or assess all significant
risk
factors.
Sources
of target businesses
We
anticipate that target business candidates will be brought to our attention
from
various unaffiliated sources, including investment bankers, venture capital
funds, private equity funds, leveraged buyout funds, management buyout funds
and
other members of the financial community, who may present solicited or
unsolicited proposals. Our officers and directors as well as their affiliates
may also bring to our attention target business candidates. While we do not
presently anticipate engaging the services of professional firms that specialize
in business acquisitions on any formal basis, we may engage these firms in
the
future, in which event we may pay a finder’s fee or other compensation. In no
event, however, will we pay any of our existing officers, directors or
stockholders or any entity with which they are affiliated any finder’s fee or
other compensation for services rendered to us prior to or in connection with
the consummation of a business combination. We will not enter into any business
combinations with any affiliates of our initial stockholders, officers or
directors.
Selection
of a target business and structuring of a business combination
Subject
to the requirement that our initial business combination must be with a target
business with a fair market value that is at least 80% of our net assets at
the
time of such acquisition, our management will have virtually unrestricted
flexibility in identifying and selecting a prospective target business. In
evaluating a prospective target business, (including any such target business
that may have international operations or assets) our management will consider,
among other factors, the following:
· |
financial
condition and results of operation;
|
· |
experience
and skill of management and availability of additional personnel;
|
· |
barriers
to entry into other industries;
|
· |
stage
of development of the products, processes or services;
|
· |
degree
of current or potential market acceptance of the products, processes
or
services;
|
· |
proprietary
features and degree of intellectual property or other protection
of the
products, processes or services;
|
· |
regulatory
environment of the industry; and
|
· |
costs
associated with effecting the business combination.
|
These
criteria are not intended to be exhaustive. Any evaluation relating to the
merits of a particular business combination will be based, to the extent
relevant, on the above factors as well as other considerations deemed relevant
by our management in effecting a business combination consistent with our
business objective. In evaluating a prospective target business, we will conduct
an extensive due diligence review which will encompass, among other things,
meetings with incumbent management, where applicable, and inspection of
facilities, as well as review of financial and other information which will
be
made available to us.
The
time
and costs required to select and evaluate a target business and to structure
and
complete the business combination cannot presently be ascertained with any
degree of certainty. Any costs incurred with respect to the identification
and
evaluation of a prospective target business with which a business combination
is
not ultimately completed will result in a loss to us and reduce the amount
of
capital available to otherwise complete a business combination. While
we
may pay fees or compensation to third parties for their efforts in introducing
us to a potential target business, in no event, however, will we pay any of
our
existing officers, directors or stockholders or any entity with which they
are
affiliated any finder's fee or other compensation for services rendered to
us
prior to or in connection with the consummation of a business combination,
other
than the $7,500 payable monthly in the aggregate to Equity Dynamics, Inc. and
The Lan Group for office space and certain general and administrative services.
In addition, none of our officers, directors, special advisors or existing
stockholders will receive any finder's fee, consulting fees or any similar
fees
from any person or entity in connection with any business combination involving
us other than any compensation or fees that may be received for any services
provided following such business combination.
Fair
Market Value of Target Business
The
initial target business that we acquire must have a fair market value equal
to
at least 80% of our net assets at the time of such acquisition. The fair market
value of such business will be determined by our board of directors based upon
standards generally accepted by the financial community, such as actual and
potential sales, earnings and cash flow and book value. If our board is not
able
to independently determine that the target business has a sufficient fair market
value, we will obtain an opinion from an unaffiliated, independent investment
banking firm which is a member of the National Association of Securities
Dealers, Inc. with respect to the satisfaction of such criteria. Since
any
opinion, if obtained, would merely state that fair market value meets the 80%
of
net assets threshold, it is not anticipated that copies of such opinion would
be
distributed to our stockholders, although copies will be provided to
stockholders who request it. We will not be required to obtain an opinion from
an investment banking firm as to the fair market value if our board of directors
independently determines that the target business has sufficient fair market
value.
Probable
lack of business diversification
While
we
may seek to effect business combinations with more than one target business,
our
initial business combination must be with a target business which satisfies
the
minimum valuation standard at the time of such acquisition, as discussed above.
Consequently, it is probable that we will have the ability to effect only a
single business combination. Accordingly, the prospects for our ability to
execute any potential business plan may be entirely dependent upon the future
performance of a single business. Unlike other entities which may have the
resources to complete several business combinations of entities operating in
multiple industries or multiple areas of a single industry, it is probable
that
we will not have the resources to diversify our operations or benefit from
the
possible spreading of risks or offsetting of losses. By consummating a business
combination with only a single entity, our lack of diversification may:
· |
subject
us to numerous economic, competitive and regulatory developments,
any or
all of which may have a substantial adverse impact upon the particular
industry in which we may operate subsequent to a business combination,
and
|
· |
result
in our dependency upon the development or market acceptance of a
single or
limited number of products, processes or services.
|
Additionally,
since our business combination may entail the simultaneous acquisitions of
several assets or operating businesses at the same time and may be with
different sellers, we will need to convince such sellers to agree that the
purchase of their assets or closely related businesses is contingent upon the
simultaneous closings of the other acquisitions.
Limited
ability to evaluate the target business’ management
Although
we expect most of our management and other key personnel, particularly our
chairman of the board, chief executive officer and president, to remain
associated with us following a business combination, they may be involved in
different capacities than at present, and we may employ other personnel
following the business combination. Although we intend to closely scrutinize
such individuals, we cannot assure you that our assessment will prove to be
correct. In addition, we cannot assure you that new members that join our
management following a business combination will have the necessary skills,
qualifications or abilities to help manage a public company.
Opportunity
for stockholder approval of business combination
Prior
to
the completion of a business combination, we will submit the transaction to
our
stockholders for approval, even if the nature of the acquisition is such as
would not ordinarily require stockholder approval under applicable state law.
In
connection with seeking stockholder approval of a business combination, we
will
furnish our stockholders with proxy solicitation materials prepared in
accordance with the Securities Exchange Act of 1934, which, among other matters,
will include a description of the operations of the target business and certain
required financial information regarding the business.
In
connection with the vote required for any business combination, all of our
existing stockholders, including all of our officers and directors, have agreed
to vote their respective shares of common stock owned by them immediately prior
to this offering in accordance with the majority of the shares of common stock
voted by the public stockholders. This voting arrangement shall not apply to
shares included in units purchased in this offering, if any, or purchased
following this offering in the open market by any of our existing stockholders,
officers and directors, and with respect to shares so acquired by existing
stockholders, the existing stockholders may vote against a proposed business
combination and exercise their conversion rights in the event that the business
combination transaction is approved.. We will proceed with the business
combination only if a majority of the shares of common stock voted by the public
stockholders are voted in favor of the business combination and public
stockholders owning less than 20% of the shares sold in this offering exercise
their conversion rights. Voting
against the business combination alone will not result in conversion of a
stockholder's shares into a pro rata share of the trust fund. Such stockholder
must have also exercised its conversion rights described below.
Conversion
rights
At
the
time we seek stockholder approval of any business combination, we will offer
each public stockholder the right to have such stockholder’s shares of common
stock converted to cash if the stockholder votes against the business
combination and the business combination is approved and completed. The actual
per-share conversion price will be equal to the amount in the trust fund,
inclusive of any interest (calculated as of two business days prior to the
consummation of the proposed business combination), divided by the number of
shares sold in this offering. Without taking into any account interest earned
on
the trust fund, the initial per-share conversion price would be $7.16 or $0.84
less than the per-unit offering price of $8.00. An eligible stockholder may
request conversion at any time after the mailing to our stockholders of the
proxy statement and prior to the vote taken with respect to a proposed business
combination at a meeting held for that purpose, but the request will not be
granted unless the stockholder votes against the business combination and the
business combination is approved and completed. Any request for conversion,
once
made, may be withdrawn at any time up to the date of the meeting. It is
anticipated that the funds to be distributed to stockholders entitled to convert
their shares who elect conversion will be distributed promptly after completion
of a business combination. Public stockholders who convert their stock into
their share of the trust fund still have the right to exercise the warrants
that
they received as part of the units. We will not complete any business
combination if public stockholders, owning 20% or more of the shares sold in
this offering, exercise their conversion rights.
Because
the initial per share conversion price is $7.16 per share (plus any interest),
which is lower than the $8.00 per unit price paid in the offering and, which
may
be lower than the market price of the common stock on the date of the
conversion, there may be a disincentive on the part of public stockholders
to
exercise their conversion rights. The term public stockholders means the holders
of common stock sold as part of the units in this offering or in the open
market, including any existing stockholders to the extent that they purchase
or
acquire such shares.
Liquidation
if no business combination
If
we do
not complete a business combination within 18 months after the consummation
of this offering, or within 24 months if the extension criteria described
below have been satisfied, we will be dissolved and will distribute to all
of
our public stockholders, in proportion to their respective equity interests,
an
aggregate sum equal to the amount in the trust fund, inclusive of any interest,
plus any remaining net assets. Our existing stockholders have waived their
rights to participate in any liquidation distribution with respect to shares
of
common stock owned by them immediately prior to this offering. There will be
no
distribution from the trust fund with respect to our warrants, which will expire
worthless.
If
we
were to expend all of the net proceeds of this offering, other than the proceeds
deposited in the trust fund, and without taking into account interest, if any,
earned on the trust fund, the initial per-share
liquidation price would be $7.16 or $0.84 less than the per-unit offering price
of $8.00. The proceeds deposited in the trust fund could, however, become
subject to the claims of our creditors which could be prior to the claims of
our
public stockholders. We cannot assure you that the actual per-share liquidation
price will not be less than $7.16, plus interest, due to claims of creditors.
Our chairman and all of our executive officers have agreed pursuant to
agreements with us and Maxim Group LLC that, if we distribute the proceeds
held
in trust to our public stockholders, they will be personally liable under
certain circumstances (for example, if a vendor does not waive any rights or
claims to the trust fund) to pay debts and obligations to vendors or other
entities that are owed money by us for services rendered or products sold to
us
in excess of the net proceeds of this offering not held in the trust account,
to
the extent necessary to ensure that such claims do not reduce the amount in
the
trust account. We cannot assure you, however, that they would be able to satisfy
those obligations.
If
we
enter into either a letter of intent, an agreement in principle or a definitive
agreement to complete a business combination prior to the expiration of 18
months after the consummation of this offering, but are unable to complete
the
business combination within the 18-month period, then we will have an additional
six months in which to complete the business combination contemplated by the
letter of intent, agreement in principle or definitive agreement. If we are
unable to do so by the expiration of the 24-month period from the consummation
of this offering, we will then liquidate. Upon notice from us, the trustee
of
the trust fund will commence liquidating the investments constituting the trust
fund and will turn over the proceeds to our transfer agent for distribution
to
our public stockholders. We anticipate that our instruction to the trustee
would
be given promptly after the expiration of the applicable 18-month or 24-month
period.
Our
public stockholders shall be entitled to receive funds from the trust fund
only
in the event of our liquidation or if the stockholders seek to convert their
respective shares into cash upon a business combination which the stockholder
voted against and which is actually completed by us. In no other circumstances
shall a stockholder have any right or interest of any kind to or in the trust
fund. Voting
against the business combination alone will not result in conversion of a
stockholder's shares into a pro rata share of the trust fund. Such stockholder
must have also exercised its conversion rights described above.
Competition
for Target Businesses
In
identifying, evaluating and selecting a target business, we may encounter
intense competition from other entities having a business objective similar
to
ours. Many of these entities are well established and have extensive experience
identifying and effecting business combinations directly or through affiliates.
Many of these competitors possess greater technical, human and other resources
than us and our financial resources will be relatively limited when contrasted
with those of many of these competitors. While we believe there are numerous
potential target businesses that we could acquire with the net proceeds of
this
offering, our ability to compete in acquiring certain sizable target businesses
will be limited by our available financial resources. This inherent competitive
limitation gives others an advantage in pursuing the acquisition of a target
business. Further:
· |
our
obligation to seek stockholder approval of a business combination
or
obtain the necessary financial information to be included in the
proxy
statement to be sent to stockholders in connection with such business
combination may delay or prevent the completion of a transaction;
|
· |
our
obligation to convert into cash shares of common stock held by our
public
stockholders in certain instances may reduce the resources available
to us
for a business combination;
|
· |
our
outstanding warrants and options, and the future dilution they potentially
represent, may not be viewed favorably by certain target businesses;
and
|
· |
the
requirement to acquire assets or an operating business that has a
fair
market value equal to at least 80% of our net assets at the time
of the
acquisition could require us to acquire several assets or closely
related
operating businesses at the same time, all of which sales would be
contingent
on the closings of the other sales, which could make it more difficult
to
consummate the business combination.
|
Additionally,
we face competition from other
blank-check companies which have formed recently, a number of which may
consummate a business combination in any industry they choose. We may therefore
be subject to competition from these companies, which are seeking to consummate
a business plan similar to ours and which will, as a result, increase demand
for
privately-held companies to combine with companies structured similarly to
ours.
Further, the fact that only one of such companies has completed a business
combination and three of such companies have entered into a definitive agreement
for a business combination may be an indication that there are only a limited
number of attractive target businesses available to such entities or that many
privately-held target businesses may not be inclined to enter into business
combinations with publicly held blank check companies like us.
Any
of
these factors may place us at a competitive disadvantage in negotiating a
business combination. Our management believes, however, that our status as
a
public entity and potential access to the United States public equity markets
may give us a competitive advantage over privately-held entities having a
similar business objective as us in acquiring a target business with significant
growth potential on favorable terms.
If
we
effect a business combination, there will be, in all likelihood, intense
competition from competitors of the target business. We cannot assure you that,
subsequent to a business combination, we will have the resources or ability
to
compete effectively.
Facilities
We
maintain our executive offices at 2116 Financial Center, 666 Walnut Street,
Des
Moines, Iowa 50309. We have agreed to pay Equity Dynamics, Inc., an affiliated
third party of which Mr. Pappajohn is the President and principal stockholder,
and Mr. Kinley a Senior Vice President, approximately $6,000 per month for
office space (located at our executive offices) and certain additional general
and administrative services, such as an allocable share of receptionist,
secretarial and general office services. These offices consist of approximately
2,570 square feet of office space. We have also agreed to pay another affiliated
third party, The Lan Group, of which Dr. Schaffer is the sole owner,
approximately $1,500 per month for office space (located in Rochester, New
York)
and certain additional general and administrative services, such as an allocable
share of receptionist, secretarial and general office services.
We
consider our current office space adequate for our current operations.
Employees
We
have
three officers, all of whom are also members of our board of directors. These
individuals are not obligated to contribute any specific number of hours per
week and intend to devote only as much time as they deem necessary to our
affairs. The amount of time they will devote in any time period will vary based
on the availability of suitable target businesses to investigate, although
we
expect such individuals to devote an average of approximately ten hours per
week
to our business. We do not intend to have any full time employees prior to
the
consummation of a business combination.
Periodic
Reporting and Financial Information
We
have
registered our units, common stock and warrants under the Securities Exchange
Act of 1934, as amended, and have reporting obligations, including the
requirement that we file annual and quarterly reports with the SEC. In
accordance with the requirements of the Securities Exchange Act of 1934, our
annual reports will contain financial statements audited and reported on by
our
independent accountants.
We
will
not acquire an operating business in the healthcare industry if audited
financial statements based on United States generally accepted accounting
principles cannot be obtained for such target business. Alternatively, we will
not acquire assets if the financial information called for by applicable law
cannot be obtained for such assets. Additionally, our management will provide
stockholders with the foregoing financial information as part of the proxy
solicitation materials sent to stockholders to assist them in assessing each
specific target business or assets we seek to acquire. Our management believes
that the requirement of having available financial information for the target
business or assets may limit the pool of potential target businesses or assets
available for acquisition.
Legal
Proceedings
To
the
knowledge of our management, there is no litigation currently pending or
contemplated against us or any of our officers or directors in their capacity
as
such.
Comparison
to Offerings of Blank Check Companies
The
following table compares and contrasts the terms of our offering and the terms
of an offering of blank check companies under Rule 419 promulgated by
the
SEC assuming that the gross proceeds, underwriting discounts and underwriting
expenses for the Rule 419 offering are the same as this offering and
that
the underwriters will not exercise their over-allotment option. None of the
terms of a Rule 419 offering will apply to this offering.
|
Terms
of Our Offering
|
|
Terms
Under a Rule 419 Offering
|
Escrow
of offering proceeds
|
$42,960,000
of the net offering proceeds will be deposited into a trust account
at JP
Morgan Chase NY Bank maintained by Continental Stock Transfer &
Trust Company.
|
|
$40,176,000
would be required to be deposited into either an escrow account
with an
insured depositary institution or in a separate bank account established
by a broker-dealer in which the broker-dealer acts as trustee for
persons
having the beneficial interests in the account.
|
Investment
of net proceeds
|
The
$42,960,000 of net offering proceeds held in trust will only be
invested
in U.S. “government securities,” defined as any Treasury Bill issued by
the United States having a maturity of one hundred and eighty days
or
less.
|
|
Proceeds
could be invested only in specified securities such as a money
market fund
meeting conditions of the Investment Company Act of 1940 or in
securities
that are direct obligations of, or obligations guaranteed as to
principal
or interest by, the United States.
|
Limitation
on fair value or
net assets
of
target business
|
The
initial target business that we acquire must have a fair market
value
equal to at least 80% of our net assets at the time of such acquisition.
|
|
We
would be restricted from acquiring a target business unless the
fair value
of such business or net assets to be acquired represent at least
80% of
the maximum offering proceeds.
|
Trading
of securities issued
|
The
units shall commence trading on or promptly after the date of this
prospectus. The common stock and warrants comprising the units
shall begin
to trade separately on the 90th day after the date of this prospectus
unless Maxim Group LLC informs us of its decision to allow earlier
separate trading, provided we have filed with the SEC a Current
Report on
Form 8-K, which includes an audited balance sheet reflecting our
receipt
of the proceeds of this offering, including any proceeds we receive
from
the exercise of the over-allotment option, if such option is exercised
prior to the filing of the Form 8-K. Thereafter the units will
no longer
trade.
|
|
No
trading of the units or the underlying common stock and warrants
would be
permitted until the completion of a business combination. During
this
period, the securities would be held in the escrow or trust
account.
|
Exercise
of the warrants
|
The
warrants cannot be exercised until the later of the completion
of a
business combination or one year from the date of this prospectus
and,
accordingly, will only be exercised after the trust fund has been
terminated and distributed.
|
|
The
warrants could be exercised prior to the completion of a business
combination, but securities received and cash paid in connection
with the
exercise would be deposited in the escrow or trust
account.
|
Election
to remain an
investor
|
We
will give our stockholders the opportunity to vote on the business
combination. In connection with seeking stockholder approval, we
will send
each stockholder a proxy statement containing information required
by the
SEC. A stockholder following the procedures described in this prospectus
is given the right to convert his or her shares into his or her
pro rata
share of the trust fund. However, a stockholder who does not follow
these
procedures or a stockholder who does not take any action would
not be
entitled to the return of any funds.
|
|
A
prospectus containing information required by the SEC would be
sent to
each investor. Each investor would be given the opportunity to
notify the
company, in writing, within a period of no less than 20 business
days and
no more than 45 business days from the effective date of the
post-effective amendment, to decide whether he or she elects to
remain a
stockholder of the company or require the return of his or her
investment.
If the company has not received the notification by the end of
the
45th
business
day, funds and interest or dividends, if any, held in the trust
or escrow
account would automatically be returned to the stockholder. Unless
a
sufficient number of investors elect to remain investors, all of
the
deposited funds in the escrow account must be returned to all investors
and none of the securities will be issued.
|
Business
combination deadline
|
A
business combination must occur within 18 months after the consummation
of
this offering or within 24 months after the consummation of this
offering
if a letter of intent or definitive agreement relating to a prospective
business combination was entered into prior to the end of the 18-month
period.
|
|
If
an acquisition has not been consummated within 18 months after
the
effective date of the initial registration statement, funds held
in the
trust or escrow account would be returned to investors.
|
Release
of funds
|
The
proceeds held in the trust account will not be released until the
earlier
of the completion of a business combination or our liquidation
upon our
failure to effect a business combination within the allotted
time.
|
|
The
proceeds held in the escrow account would not be released until
the
earlier of the completion of a business combination or the failure
to
effect a business combination within the allotted
time.
|
MANAGEMENT
Directors
and Executive Officers
Our
current directors and executive officers are as follows:
Name
|
Age
|
Position
|
John
Pappajohn
|
76
|
Chairman
and Secretary
|
Derace
L. Schaffer, M.D.
|
57
|
Vice-Chairman
and Chief Executive Officer
|
Matthew
P. Kinley
|
37
|
President,
Treasurer and Director
|
Edward
B. Berger
|
76
|
Director
|
Wayne
A. Schellhammer
|
52
|
Director
|
John
Pappajohn
has
served as our chairman and secretary since April 2005. Since 1969, Mr. Pappajohn
has been the President and principal stockholder of Equity Dynamics, Inc.,
a
financial consulting firm, and the sole owner of Pappajohn Capital Resources,
a
venture capital firm. He also serves as a director of the following public
companies: Allion Healthcare, Inc., MC Informatics, Inc., PACE Health Management
Systems, Inc. and Patient InfoSystems, Inc. Mr. Pappajohn has been an active
private equity investor in healthcare companies for more than 30 years and
has
served as a director of more than 40 public companies. Mr. Pappajohn has been
a
founder in several public healthcare companies such as Caremark Rx, Inc.,
Quantum Health Resources, and Radiologix, Inc. Mr. Pappajohn and Dr. Schaffer
have worked together for more than fifteen years on a variety of healthcare
companies, and they have co-founded Allion Healthcare, Inc., Patient
Infosystems, Inc., and Radiologix, Inc., all of which are public companies.
In
addition, Mr. Pappajohn and Dr. Schaffer have worked together on many private
healthcare companies, such as Logisticare, Inc. and Source Medical Corporation.
Mr. Pappajohn received his B.S.C. from the University of Iowa.
Derace
L. Schaffer, M.D.
has
served as our vice chairman and chief executive officer since April 2005. Dr.
Schaffer is the founder and CEO of The Lan Group, a venture capital firm
specializing in healthcare and high technology investments. He serves as a
director of Allion Healthcare, Inc. and Patient InfoSystems, Inc., both public
companies. He has served as chairman of several healthcare companies including,
Radiologix, Inc when it was private. He has been an active co-investor with
Mr.
Pappajohn for more than fifteen years on a variety of healthcare companies,
and
they have co-founded Allion Healthcare, Patient Infosystems and Radiologix,
all
of which are public companies. In addition, Mr. Pappajohn and Dr. Schaffer
have
worked together on many private healthcare companies, such as Logisticare,
Inc.
and Source Medical Corporation. Dr. Schaffer served as chief executive officer
and chairman of the board of Ide Imaging Group, P.C. from 1980 to 2001. Dr.
Schaffer has served as a director on many healthcare boards of directors
including several health systems and more than ten healthcare services and
technology companies. Dr. Schaffer received his postgraduate radiology training
at Harvard Medical School and Massachusetts General Hospital, where he served
as
Chief Resident. Dr. Schaffer is currently also a Clinical Professor of Radiology
at Weill Cornell Medical College.
Matthew
P. Kinley
has
served as our president, treasurer and a director since April 2005. Since 1995,
he has served as Senior Vice President of Equity Dynamics, Inc., a financial
consulting firm, and Pappajohn Capital Resources, a venture capital firm, both
owned by John Pappajohn. Mr. Kinley has been involved in the financing and
development of more than 20 companies with Mr. Pappajohn in the past ten years.
Mr. Kinley has worked with Dr. Schaffer for more than ten years on healthcare
services and technology companies. From 1990 through 1995, Mr. Kinley was
manager and held various positions at KPMG Peat Marwick, working on tax, audit
and merger and acquisition issues. Mr. Kinley received his B.A. in Business,
with highest honors, from the University of Northern Iowa in May 1990.
Edward
B. Berger
has
served as a director since April 2005. Mr. Berger is currently a member of
the
Board, on the Audit Committee and Finance Committee of Patient InfoSystems,
Inc., a public company. He is Chairman and Chief Executive Officer of Equity
Acquisitions Incorporated, a position he has held since January 2004, Chairman
of the Board of Directors of Southwest Business Systems, Chairman and CEO of
Berger Equities Inc., director and Chairman of the Audit Committee of
CardSystems Solutions and a director of Compass Bank of Tucson, AZ., a public
company. Mr. Berger has extensive healthcare experience: past President and
CEO
of Palo Verde Hospital; past President and member of the Board of Trustees
of
Kino Community Hospital; past member of the Long Range Planning Committee of
Tucson Medical Center, all in Tucson, AZ. Mr. Berger is currently an Adjunct
Professor in Political Science at Pima Community College and is the Chairman
of
the MBA Advisory Council, Eller Graduate School of Management at the University
of Arizona. He has been admitted to practice law before the U.S. Supreme Court,
U.S. Court of Appeals for the 9th Circuit and the U.S. District Court-Arizona.
He is admitted to the New York Bar, the Arizona Bar and the District of Columbia
Bar. Mr. Berger received his Juris Doctor degree from New York Law
School.
Wayne
A. Schellhammer
has
served as a director since June 2005. Mr. Schellhammer is Chairman and Chief
Executive Officer of American Care Source Holdings, Inc., a private company,
a
position he has held since October of 2004. He served as President and CEO
of
Iowa Health Physicians, an affiliate of the Iowa Health System, for five years,
as President and CEO of InTrust for five years and as Vice President of
Physician Services and Payer Contracting for the Iowa Health System, a hospital
and physician integrated health system, for five years. Mr. Schellhammer has
also held senior executive positions with KPMG Consulting (now BearingPoint)
for
two years, Wellcare of New York, a subsidiary of a public company, Wellcare
HealthPlans, Inc., for five years, as well as a national cardiac consulting
firm. He has spent a total of 30 years in the healthcare industry and is a
graduate of the University of Minnesota.
Our
board
of directors is divided into two classes with only one class of directors being
elected in each year and each class serving a two-year term. The term of office
of the first class of directors, consisting of Mr. Berger and Mr. Schellhammer,
will expire at our first annual meeting of stockholders. The term of office
of
the second class of directors, consisting of Mr. Pappajohn, Dr. Schaffer and
Mr.
Kinley, will expire at the second annual meeting.
These
individuals will play a key role in identifying and evaluating prospective
acquisition candidates, selecting the target business, and structuring,
negotiating and consummating its acquisition. None of these individuals has
been
a principal of or affiliated with a public company or blank check company that
executed a business plan similar to our business plan and none of these
individuals is currently affiliated with such an entity. However, we believe
that the skills and expertise of these individuals, their collective access
to
acquisition opportunities and ideas, their contacts, and their transaction
expertise should enable them to identify and effect an acquisition although
we
cannot assure you that they will, in fact, be able to do so.
Executive
Compensation
No
executive officer has received any cash compensation for services rendered.
No
compensation of any kind, including finder’s and consulting fees, will be paid
to any of our existing stockholders, including our officers and directors,
or
any of their respective affiliates, for services rendered prior to or in
connection with a business combination. However, these individuals will be
reimbursed for any out-of-pocket expenses incurred in connection with activities
on our behalf such as identifying potential target businesses and performing
due
diligence on suitable business combinations. There is no limit on the amount
of
these out-of-pocket expenses and there will be no review of the reasonableness
of the expenses by anyone other than our board of directors, which includes
persons who may seek reimbursement, or a court of competent jurisdiction if
such
reimbursement is challenged. If all of our directors are not deemed
“independent,” we will not have the benefit of independent directors examining
the propriety of expenses incurred on our behalf and subject to reimbursement.
We
have
agreed to pay Equity Dynamics, Inc., an affiliated third party of which Mr.
Pappajohn is the President and principal stockholder, and Mr. Kinley a Senior
Vice President, approximately $6,000 per month for office space and certain
additional general and administrative services. We have also agreed to pay
another affiliated third party, The Lan Group, of which Dr. Schaffer is the
sole
owner, approximately $1,500 per month for office space and certain additional
general and administrative services.
Conflicts
of Interest
Potential
investors should be aware of the following potential conflicts of interest:
· |
None
of our officers or directors is required to commit their full time
to our
affairs and, accordingly, they may have conflicts of interest in
allocating management time among various business activities.
|
· |
In
the course of their other business activities, our officers and directors
may become aware of investment and business opportunities which may
be
appropriate for presentation to us as well as the other entities
with
which they are affiliated. They may have conflicts of interest in
determining to which entity a particular business opportunity should
be
presented. For a complete description of our management’s other
affiliations, see the previous section entitled “Directors and Executive
Officers.”
|
· |
Our
officers and directors may in the future become affiliated with entities,
including other blank check companies, engaged in business activities
similar to those intended to be conducted by us.
|
· |
Since
our directors own shares of our common stock which will be released
from
escrow only in certain limited situations, our board may have a conflict
of interest in determining whether a particular target business is
appropriate to effect a business combination. The personal and financial
interests of our directors and officers may influence their motivation
in
identifying and selecting a target business and completing a business
combination timely.
|
In
general, officers and directors of a corporation incorporated under the laws
of
the State of Delaware are required to present business opportunities to a
corporation if:
· |
the
corporation could financially undertake the opportunity;
|
· |
the
opportunity is within the corporation’s line of business; and
|
· |
it
would not be fair to the corporation and its stockholders for the
opportunity not to be brought to the attention of the corporation.
|
Accordingly,
as a result of multiple business affiliations, our officers and directors may
have similar legal obligations relating to presenting business opportunities
meeting the above-listed criteria to multiple entities. In addition, conflicts
of interest may arise when our board evaluates a particular business opportunity
with respect to the above-listed criteria. We cannot assure you that any of
the
above mentioned conflicts will be resolved in our favor.
In
order
to minimize potential conflicts of interest which may arise from multiple
corporate affiliations, each of our officers and directors has agreed in
principle, until the earlier of a business combination, our liquidation or
such
time as he ceases to be an officer or director, to present to us for our
consideration, prior to presentation to any other entity, any business
opportunity which may reasonably be required to be presented to us under
Delaware law, subject to any pre-existing fiduciary obligations they might
have.
Each
of
our directors has, or may come to have, to a certain degree, other fiduciary
obligations. In addition all of our officers and directors have fiduciary
obligations to those companies on whose board of directors they sit. To the
extent that they identify business opportunities that may be suitable for the
entities to which they owe a fiduciary obligation, our officers and directors
will honor those fiduciary obligations. Accordingly, they may not present
opportunities to us that otherwise may be attractive to us unless the entities
to which they owe a fiduciary obligation and any successors to such entities
have declined to accept such opportunities. Additionally, certain of our
directors and officers are directors of companies, both public and private,
which may perform business activities in the healthcare industry similar to
those which we may perform after consummating a business combination. Mr.
Pappajohn is a director of the following such public companies: Patient
InfoSystems, Inc. and Allion Healthcare, Inc., as well as the following such
private companies: American CareSource Holdings, Inc. and Partners Imaging
LLC.
Dr. Schaffer is a director of the following such public companies: Patient
InfoSystems, Inc. and Allion Healthcare, Inc., as well as the following such
private companies: American CareSource Holdings, Inc., Partners Imaging LLC
and
CareCore National, Inc. Mr. Berger is a director of the following such public
company: Patient InfoSystems, Inc. Mr. Schellhammer is a director of the
following private company: American CareSource Holdings, Inc.
In
connection with the vote required for any business combination, all of our
existing stockholders, including all of our officers and directors, have agreed
to vote their respective shares of common stock which were owned prior to this
offering in accordance with the vote of the public stockholders owning a
majority of the shares of our common stock sold in this offering. Any
shares of common stock acquired by existing stockholders in the open market
will
be considered as part of the holdings of public stockholders and will have
the
same rights as other public stockholders, including voting and conversion rights
with respect to a potential business combination, and the
existing stockholders may thus vote against a proposed business combination
with
respect to such shares.
Accordingly, they may vote on a proposed business combination with respect
to
shares acquired in the open market any way they so choose. In addition, they
have agreed to waive their respective rights to participate in any liquidation
distribution occurring upon our failure to consummate a business combination
but
only with respect to those shares of common stock acquired by them prior to
this
offering and not with respect to any shares acquired in the open market.
To
further minimize potential conflicts of interest, we have agreed not to
consummate a business combination with an entity which is affiliated with any
of
our existing stockholders unless we obtain an opinion from an independent
investment banking firm that the business combination is fair to our
stockholders from a financial point of view. We expect that any such opinion
will be included in our proxy solicitation materials, furnished to stockholders
in connection with their vote on such a business combination.
PRINCIPAL
STOCKHOLDERS
The
following table sets forth information regarding the beneficial ownership of
our
common stock as of April 30, 2005, and as adjusted to reflect the sale of our
common stock included in the units offered by this prospectus (assuming no
purchase of units in this offering), by:
· |
each
person known by us to be the beneficial owner of more than 5% of
our
outstanding shares of common stock;
|
· |
each
of our officers and directors; and
|
· |
all
our officers and directors as a group.
|
Unless
otherwise indicated, we believe that all persons named in the table have sole
voting and investment power with respect to all shares of common stock
beneficially owned by them.
|
|
Amount
and
Nature
|
|
Approximate
Percentage
of
Outstanding Common Stock
|
Name
and Address of Beneficial Owner(1)
|
|
of
Beneficial Ownership
|
|
Before
the Offering
|
After
the Offering(2)
|
John
Pappajohn
|
|
|
588,000
|
|
|
|
39.20
|
%
|
|
|
7.84
|
%
|
|
Derace
L. Schaffer, M.D.
|
|
|
588,000
|
|
|
|
39.20
|
%
|
|
|
7.84
|
%
|
|
Matthew
P. Kinley
|
|
|
294,000
|
|
|
|
19.60
|
%
|
|
|
3.92
|
%
|
|
Edward
B. Berger
|
|
|
15,000
|
|
|
|
1.00
|
%
|
|
|
.20
|
%
|
|
Wayne
A. Schellhammer
|
|
|
15,000
|
|
|
|
1.00
|
%
|
|
|
.20
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All
directors and executive officers as a group (four individuals)
|
|
|
1,500,000
|
|
|
|
100
|
%
|
|
|
20
|
%
|
|
(1) |
Unless
otherwise indicated, the business address of each of the individuals
is
2116 Financial Center,
666 Walnut Street, Des Moines, Iowa 50309.
|
(2) |
Assumes
only the sale of 6,000,000 units in this offering, but not the exercise
of
the 6,000,000 warrants
to purchase our common stock included in such units.
|
John
Pappajohn, our chairman and secretary, or his designees, has agreed to purchase
up to $1,000,000 of our warrants on the open market, at a price per warrant
not
to exceed $1.20, within three months of such warrants being separately
tradeable. These warrants will not be sold until the consummation of a business
combination. None of our other existing stockholders, officers and directors
has
indicated to us that they intend to purchase units in the offering or warrants
on the open market. Immediately after this offering, our existing stockholders,
which include all of our officers and directors, collectively, will beneficially
own 20% of the then issued and outstanding shares of our common stock. Because
of this ownership block, these stockholders may be able to effectively influence
the outcome of all matters requiring approval by our stockholders, including
the
election of directors and approval of significant corporate transactions other
than approval of a business combination.
All
of
the shares of our common stock outstanding prior to the date of this prospectus
will be placed in escrow with Continental Stock Transfer & Trust
Company, as escrow agent, until the earliest of:
· |
three
years following the date of this prospectus;
or
|
· |
the
consummation of a liquidation, merger, stock exchange or other similar
transaction which results in all of our stockholders having the right
to
exchange their shares of common stock for cash, securities or other
property subsequent to our consummating a business combination with
a
target business.
|
Dr.
Schaffer, Mr. Pappajohn and Mr. Kinley each may be deemed to be our “parent” and
“promoter,” as these terms are defined under the Federal securities laws.
In
April
2005, we issued 1,500,000 shares of our common stock to the individuals set
forth below for an aggregate amount of $25,000 in cash, at an average purchase
price of approximately $0.0167 per share, as follows:
Name
|
Number
of Shares
|
Relationship
to Us
|
|
John
Pappajohn
|
600,000
|
Chairman
and Secretary
|
|
Derace
L. Schaffer, M.D.
|
600,000
|
Vice-Chairman
and CEO
|
|
Matthew
P. Kinley
|
300,000
|
President,
Treasurer and director
|
|
Further,
in June 2005, Mr. Pappajohn, Dr. Schaffer and Mr. Kinley transferred, for the
same consideration per share which they paid to us and pro rata to their
ownership of our common stock, an aggregate of 30,000 shares of our common
stock
equally to Mr. Berger and Mr. Schellhammer, such that our current share
ownership is as reflected in the section entitled “Principal
Stockholders”.
The
holders of the majority of these shares will be entitled to require us, on
up to
two occasions, to register these shares pursuant to an agreement to be signed
prior to or on the date of this prospectus. The holders of the majority of
these
shares may elect to exercise these registration rights at any time after the
date on which these shares of common stock are released from escrow, which,
except in limited circumstances, is not before three years from the date of
this
prospectus. In addition, these stockholders have certain “piggy-back”
registration rights on registration statements filed subsequent to the date
on
which these shares of common stock are released from escrow. We will bear the
expenses incurred in connection with the filing of any such registration
statements.
As
of the
date of this prospectus, Mr. Pappajohn, Dr. Schaffer and Mr. Kinley have loaned
us a total of $175,000 which was used to pay a portion of the expenses of this
offering, such as SEC registration fees, NASD registration fees and legal and
accounting fees and expenses. These loans will be payable without interest
on
the earlier of April 28, 2006 or the consummation of this offering. The loans
will be repaid out of the net proceeds of this offering not being placed in
trust.
John
Pappajohn, our chairman and secretary, or his designees, has agreed to purchase
up to $1,000,000 of our warrants on the open market, at a price per warrant
not
to exceed $1.20, within three months of such warrants being separately
tradeable. These warrants will not be sold until the consummation of a business
combination. Maxim Group LLC has also agreed to purchase up to $500,000 of
our
warrants on the open market on similar terms.
We
have
agreed to pay Equity Dynamics, Inc., an affiliated third party of which Mr.
Pappajohn is the President and principal stockholder, and Mr. Kinley a Senior
Vice President, approximately $6,000 per month for office space and certain
additional general and administrative services. We have also agreed to pay
another affiliated third party, The Lan Group, of which Dr. Schaffer is the
sole
owner, approximately $1,500 per month for office space and certain additional
general and administrative services.
Other
than the reimbursable out-of-pocket expenses payable to our officers and
directors, no compensation or fees of any kind, including finders and consulting
fees, will be paid to any of our existing stockholders, officers or directors
who owned our common stock prior to this offering, or to any of their respective
affiliates for services rendered to us prior to or with respect to the business
combination.
After
the
consummation of a business combination, if any, to the extent our management
remains as officers of the resulting business, we anticipate that our officers
and directors may enter into employment agreements, the terms of which shall
be
negotiated and which we expect to be comparable to employment agreements with
other similarly-situated companies in the healthcare industry. Further, after
the consummation of a business combination, if any, to the extent our directors
remain as directors of the resulting business, we anticipate that they will
receive compensation comparable to directors at other similarly-situated
companies in the healthcare industry.
All
ongoing and future transactions between us and any of our officers and directors
or their respective affiliates, including loans by our officers and directors,
will be on terms believed by us to be no less favorable than are available
from
unaffiliated third parties and such transactions or loans, including any
forgiveness of loans, will require prior approval in each instance by a majority
of our uninterested “independent” directors (to the extent we have any) or the
members of our board who do not have an interest in the transaction, in either
case who had access, at our expense, to our attorneys or independent legal
counsel.
General
We
are
authorized to issue 100,000,000 shares of common stock, par value $.0001, and
1,000,000 shares of preferred stock, par value $.0001. As of the date of this
prospectus, 1,500,000 shares of common stock are outstanding, held by three
record holders. No shares of preferred stock are currently outstanding.
Units
Each
unit
consists of one share of common stock and one warrant. Each warrant entitles
the
holder to purchase one share of common stock. The common stock and warrants
shall begin to trade separately on the 90th
day
after
the date of this prospectus unless Maxim Group LLC informs us of its decision
to
allow earlier separate trading, provided that in no event may the common stock
and warrants be traded separately until we have filed with the SEC a Current
Report on Form 8-K which includes an audited balance sheet reflecting
our
receipt of the gross proceeds of this offering. Thereafter the units will no
longer trade as units. We will file a Current Report on Form 8-K
which
includes this audited balance sheet upon the consummation of this offering.
The
audited balance sheet will reflect proceeds we receive from the exercise of
the
over-allotment option, if the over-allotment option is exercised prior to the
filing of the Form 8-K.
Common
Stock
Our
stockholders are entitled to one vote for each share held of record on all
matters to be voted on by stockholders. In connection with the vote required
for
any business combination, all of our existing stockholders, including all of
our
officers and directors, have agreed to vote their respective shares of common
stock owned by them immediately prior to this offering in accordance with the
public stockholders. This voting arrangement shall not apply to shares included
in units purchased in this offering, if any, or purchased following this
offering in the open market by any of our existing stockholders, officers and
directors. Additionally, our existing stockholders, officers and directors
will
vote all of their shares in any manner they determine, in their sole discretion,
with respect to any other items that come before a vote of our stockholders.
We
will
proceed with the business combination only if a majority of the shares of common
stock voted by the public stockholders are voted in favor of the business
combination and public stockholders owning less than 20% of the shares sold
in
this offering exercise their conversion rights discussed below. Voting
against the business combination alone will not result in conversion of a
stockholder's shares into a pro rata share of the trust fund. Such stockholder
must have also exercised its conversion rights described below.
Our
board
of directors is divided into two classes, each of which will generally serve
for
a term of two years with only one class of directors being elected in each
year.
There is no cumulative voting with respect to the election of directors, with
the result that the holders of more than 50% of the shares voted for the
election of directors can elect all of the directors.
If
we are
forced to liquidate prior to a business combination, our public stockholders
are
entitled to share ratably in the trust fund, inclusive of any interest, and
any
net assets remaining available for distribution to them after payment of
liabilities. The
term
public stockholders means the holders of common stock sold as part of the units
in this offering or in the open market, including any existing stockholders
to
the extent that they purchase or acquire such shares. Our existing stockholders
have agreed to waive their respective rights to participate in any liquidation
distribution occurring upon our failure to consummate a business combination,
but only with respect to those shares of common stock acquired by them prior
to
this offering.
Our
stockholders have no conversion, preemptive or other subscription rights and
there are no sinking fund or redemption provisions applicable to the common
stock, except that public stockholders have the right to have their shares
of
common stock converted to cash equal to their pro rata share of the trust fund
if they vote against the business combination and the business combination
is
approved and completed. Public stockholders who convert their stock into their
share of the trust fund still have the right to exercise the warrants that
they
received as part of the units.
Preferred
Stock
Our
certificate of incorporation authorizes the issuance of 1,000,000 shares of
blank check preferred stock with such designation, rights and preferences as
may
be determined from time to time by our board of directors. No shares of
preferred stock are being issued or registered in this offering. Accordingly,
our board of directors is empowered, without stockholder approval, to issue
preferred stock with dividend, liquidation, conversion, voting or other rights
which could adversely affect the voting power or other rights of the holders
of
common stock, although the underwriting agreement prohibits us, prior to a
business combination, from issuing preferred stock which participates in any
manner in the proceeds of the trust fund, or which votes as a class with the
common stock on a business combination. We may issue some or all of the
preferred stock to effect a business combination. In addition, the preferred
stock could be utilized as a method of discouraging, delaying or preventing
a
change in control of us. Although we do not currently intend to issue any shares
of preferred stock, we cannot assure you that we will not do so in the future.
Warrants
No
warrants are currently outstanding. Each warrant entitles the registered holder
to purchase one share of our common stock at a price of $6.00 per share, subject
to adjustment as discussed below, at any time commencing on the later of:
· |
the
completion of a business combination; or
|
· |
one
year from the date of this prospectus.
|
The
warrants will expire four years from the date of this prospectus at
5:00 p.m., New York City time.
We
may
call the warrants for redemption:
· |
in
whole and not in part;
|
· |
at
a price of $.01 per warrant at any time after the warrants become
exercisable;
|
· |
upon
not less than 30 days’ prior written notice of redemption to each
warrant holder; and
|
· |
if,
and only if, the average closing sale price of the common stock equals
or
exceeds $11.50
per share, for any 20 trading days within a 30 trading day period
ending
on the third business day prior to the notice of redemption to warrant
holders.
|
We
have
established this last criterion to provide warrant holders with a premium to
the
initial warrant exercise price as well as a degree of liquidity to cushion
the
market reaction, if any, to our redemption call. If the foregoing conditions
are
satisfied and we call the warrants for redemption, each warrant holder shall
then be entitled to exercise his or her warrant prior to the date scheduled
for
redemption, however, there can be no assurance that the price of the common
stock will exceed the call trigger price or the warrant exercise price after
the
redemption call is made.
The
exercise price and number of shares of common stock issuable on exercise of
the
warrants may be adjusted in certain circumstances including in the event of
a
stock dividend, or our recapitalization, reorganization, merger or
consolidation. However, the warrants will not be adjusted for issuances of
common stock at a price below their respective exercise prices.
The
warrants may be exercised upon surrender of the warrant certificate on or prior
to the expiration date at the offices of the warrant agent, with the exercise
form on the reverse side of the warrant certificate completed and executed
as
indicated, accompanied by full payment of the exercise price, by certified
check
payable to us, for the number of warrants being exercised. The warrant holders
do not have the rights or privileges of holders of common stock and any voting
rights until they exercise their warrants and receive shares of common stock.
After the issuance of shares of common stock upon exercise of the warrants,
each
holder will be entitled to one vote for each share held of record on all matters
to be voted on by stockholders.
No
warrants will be exercisable unless at the time of exercise a prospectus
relating to common stock issuable upon exercise of the warrants is current
and
the common stock has been registered or qualified or deemed to be exempt under
the securities laws of the state of residence of the holder of the warrants.
Under the terms of the warrant agreement, we have agreed to meet these
conditions and use our best efforts to maintain a current prospectus relating
to
common stock issuable upon exercise of the warrants until the expiration of
the
warrants. However, we cannot assure you that we will be able to do so. The
warrants may be deprived of any value and the market for the warrants may be
limited if the prospectus relating to the common stock issuable upon the
exercise of the warrants is not current or if the common stock is not qualified
or exempt from qualification in the jurisdictions in which the holders of the
warrants reside. No fractional shares will be issued upon exercise of the
warrants. If, upon exercise of the warrants, a holder would be entitled to
receive a fractional interest in a share, we will, upon exercise, round up
to
the nearest whole number the number of shares of common stock to be issued
to
the warrant holder.
John
Pappajohn, our chairman and secretary, or his designees, has agreed to purchase
up to $1,000,000 of our warrants on the open market, at a price per warrant
not
to exceed $1.20, within three months of such warrants being separately
tradeable. These warrants will not be sold until the consummation of a business
combination. Maxim Group LLC has also agreed to purchase up to $500,000 of
our
warrants in the open market on similar terms; however, Maxim Group LLC may
sell
their warrants prior to the consummation of a business combination.
Purchase
Option
We
have
agreed to sell to the representative of the underwriters an option to purchase
up to a total of 300,000 units at $10.00 per unit. The warrants issued in
conjunction with these units will be exercisable at $7.50 per share. Otherwise,
the units issuable upon exercise of this option are identical to those offered
by this prospectus. For a more complete description of the purchase option,
see
the section below entitled “Underwriting--Purchase Option.”
Dividends
We
have
not paid any dividends on our common stock to date and do not intend to pay
dividends prior to the completion of a business combination. The payment of
dividends in the future will be contingent upon our revenues and earnings,
if
any, capital requirements and general financial condition subsequent to
completion of a business combination. The payment of any dividends subsequent
to
a business combination will be within the discretion of our then board of
directors. It is the present intention of our board of directors to retain
all
earnings, if any, for use in our business operations and, accordingly, our
board
does not anticipate declaring any dividends in the foreseeable future.
Our
Transfer Agent and Warrant Agent
The
transfer agent for our securities and warrant agent for our warrants is
Continental Stock Transfer & Trust Company, 17 Battery Place, New York,
New York 10004.
Shares
Eligible for Future Sale
Immediately
after this offering, we will have 7,500,000 shares of common stock outstanding,
or 8,400,000 shares if the underwriters’ over-allotment option is exercised in
full. Of these shares, the 6,000,000 shares sold in this offering, or 6,900,000
shares if the over-allotment option is exercised in full, will be freely
tradable without restriction or further registration under the Securities Act,
except for any shares
purchased by one of our affiliates within the meaning of Rule 144 under
the
Securities Act. All of the remaining 1,500,000 shares are restricted securities
under Rule 144, in that they were issued in private transactions not
involving a public offering. None of those will be eligible for sale under
Rule 144 prior to April 25, 2006. Notwithstanding this, all of those
shares
have been placed in escrow and will not be transferable for a period of three
years from the date of this prospectus and will only be released prior to that
date subject to certain limited exceptions, such as our liquidation prior to
a
business combination (in which case the certificate representing such shares
will be destroyed), and the consummation of a liquidation, merger, stock
exchange or other similar transaction which results in all of our stockholders
having the right to exchange their shares of common stock for cash, securities
or other property subsequent to our consummating a business combination with
a
target business.
Rule 144
In
general, under Rule 144 as currently in effect, a person who has
beneficially owned restricted shares of our common stock for at least one year
would be entitled to sell within any three-month period a number of shares
that
does not exceed the greater of either of the following:
· |
1%
of the number of shares of common stock then outstanding, which will
equal
75,000 shares immediately after this offering (or 84,000 if the
underwriters’ exercise their over-allotment option); and
|
· |
the
average weekly trading volume of the common stock during the four
calendar
weeks preceding the filing of a notice on Form 144 with respect
to
the sale.
|
Sales
under Rule 144 are also limited by manner of sale provisions and notice
requirements and to the availability of current public information about us.
Rule 144(k)
Under
Rule 144(k), a person who is not deemed to have been one of our affiliates
at the time of or at any time during the three months preceding a sale, and
who
has beneficially owned the restricted shares proposed to be sold for at least
two years, including the holding period of any prior owner other than an
affiliate, is entitled to sell their shares without complying with the manner
of
sale, public information, volume limitation or notice provisions of
Rule 144.
SEC
Position on Rule 144 Sales
The
Securities and Exchange Commission has taken the position that promoters or
affiliates of a blank check company and their transferees, both before and
after
a business combination, would act as an “underwriter” under the Securities Act
when reselling the securities of a blank check company. Accordingly, the
Securities and Exchange Commission believes that those securities can be resold
only through a registered offering and that Rule 144 would not be available
for those resale transactions despite technical compliance with the requirements
of Rule 144.
Registration
Rights
The
holders of our 1,500,000 issued and outstanding shares of common stock on the
date of this prospectus will be entitled to registration rights pursuant to
an
agreement to be signed prior to or on the effective date of this offering.
The
holders of the majority of these shares are entitled to require us, on up to
two
occasions, to register these shares. The holders of the majority of these shares
can elect to exercise these registration rights at any time after the date
on
which these shares of common stock are released from escrow. In addition, these
stockholders have certain “piggy-back” registration rights on registration
statements filed subsequent to the date on which these shares of common stock
are released from escrow. We will bear the expenses incurred in connection
with
the filing of any such registration statements.
UNDERWRITING
Maxim
Group LLC is lead managing underwriter of the offering and is acting as
representative of the underwriters named below. Subject to the terms and
conditions in the underwriting agreement, each underwriter named below has
agreed to purchase from us, on a firm commitment basis, the respective number
of
units shown opposite its name below, at the public offering price, less the
underwriting discount set forth on the cover page of this
prospectus:
Underwriter
|
|
Number
of Units
|
|
Maxim
Group LLC
|
|
|
|
Total
|
|
|
6,000,000
|
|
The
underwriting agreement provides that the underwriters are committed to purchase
all of the units offered by this prospectus if they purchase any of the units.
This commitment does not apply to the units subject to an over-allotment option
granted by us to the underwriters to purchase additional units in
this offering.
The underwriting agreement also provides that the obligations of the
underwriters to pay for and accept delivery of the units are subject to the
passing upon of certain legal matters by counsel and certain other
conditions.
State
Blue Sky Information
We
will
offer and sell the units to retail customers only in Colorado, Delaware, the
District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland, New York,
Rhode Island and Wyoming. We have applied to have the units registered for
sale,
or we are relying on exemptions from registration in the states mentioned above.
In states that require registration, we will not sell the units in these states
until such registration is effective in each of these states (including in
Colorado, pursuant to 11-51-302(6) of the Colorado Revised Statutes).
If
you
are not an institutional investor, you may purchase our securities in this
offering only in the jurisdictions described directly above. Institutional
investors in every state except in Idaho and Oregon may purchase the units
in
this offering pursuant to exemptions provided to such entities under the Blue
Sky laws of various states. The definition of an “institutional investor” varies
from state to state but generally includes financial institutions,
broker-dealers, banks, insurance companies and other qualified entities.
Under
the
National Securities Markets Improvement Act of 1996, the states and territories
of the United States are preempted from regulating the resale by shareholders
of
the units, from and after the effective date, and the common stock and warrants
comprising the units, once they become separately transferable, because we
will
file periodic and annual reports under the Securities Exchange Act of 1934.
However, states are permitted to require notice filings and collect fees with
regard to these transactions and a state may suspend the offer and sale of
securities within such state if any such required filing is not made or fee
is
not paid. As of the date of this prospectus, the following states do not require
any notice filings or fee payments and permit the resale by shareholders of
the
units, and the common stock and warrants comprising the units, once they become
separately transferable:
Alabama,
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida,
Georgia, Guam, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine,
Massachusetts, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey,
New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South
Dakota, Utah, Virginia, Virgin Islands, Washington, West Virginia, Wisconsin
and
Wyoming.
Additionally,
the following states permit the resale by shareholders of the units, and the
common stock and warrants comprising the units, once they become separately
transferable, if the proper notice filings have been made and fees
paid:
District
of Columbia, Illinois, Maryland, Michigan, Montana, New Hampshire, North Dakota,
Oregon, Puerto Rico, Rhode Island, South Carolina, Tennessee, Texas and
Vermont.
As
of the
date of this prospectus, we have not determined in which, if any, of these
states we will submit the required filings or pay the required fee.
Additionally, if any of the states that have not yet adopted a statute, rule
or
regulation relating to the National Securities Markets Improvement Act adopts
such a statute in the future requiring a filing or fee or if any state amends
its existing statutes, rules or regulations with respect to its requirements,
we
would need to comply with those new requirements in order for the securities
to
continue to be eligible for resale in those jurisdictions.
However,
we believe that the units, from and after the effective date, and the common
stock and warrants comprising the units, once they become separately
transferable, may be eligible for sale on a secondary market basis in various
states, without any notice filings or fee payments, based upon the availability
of another applicable exemption from the state's registration
requirements.
Underwriting
Terms
Pursuant
to the underwriting agreement, we have granted to the underwriters an option,
exercisable for 45 days after the date of this prospectus, to purchase up to
an
additional 900,000 units from us on the same terms and at the same per unit
price as the other units being purchased by the underwriters from us. The
underwriters may exercise the option solely to cover over-allotments, if any,
in
the units that the underwriters have agreed to purchase from us. If the
over-allotment option is exercised in full, the total public offering price,
underwriting discounts and commissions and proceeds to us before expenses will
be $[___],
$[___]
and
$[___],
respectively.
The
following table shows the public offering price, underwriting discount to be
paid by us to the underwriters and the proceeds, before expenses, to us. This
information assumes either no exercise or full exercise by the underwriters
of
their over-allotment option.
|
|
Per
unit
|
|
Without
option
|
|
With
option
|
|
Public
offering price
|
|
$
|
8.00
|
|
$
|
48,000,000
|
|
$
|
55,200,000
|
|
Discount
(1)
|
|
$
|
0.48
|
|
$
|
2,880,000
|
|
$
|
3,312,000
|
|
Non-accountable
expense allowance(2)
|
|
$
|
0.08
|
|
$
|
480,000
|
|
$
|
480,000
|
|
Proceeds
before expenses(3)
|
|
$
|
7.44
|
|
$
|
44,640,000
|
|
$
|
51,336,000
|
|
(1) Consists
of an underwriting discount of 6% of the gross proceeds of this offering
(including any units sold to cover overallotments). Does not include an
additional underwriting discount in the amount of 1% of the gross proceeds
of
this offering (including any units sold to cover overallotments), payable out
of
the funds held in trust upon consummation of a business
combination.
(2) The
1%
non-accountable expense allowance is not payable with respect to the units
sold
upon exercise of the underwriters’ over-allotment option.
(3) The
offering expenses are estimated at $380,000.
We
have
agreed to sell the units to the underwriters at the initial public offering
price less the underwriting discount set forth on the cover page of this
prospectus. The underwriting agreement also provides that the representative
of
the underwriters will be paid a non-accountable expense allowance equal to
1% of
the gross proceeds from the sale of the units offered by this prospectus
($50,000 of which has been previously advanced to Maxim), exclusive of any
units
purchased on exercise of the over-allotment option. In the event the offering
is
terminated, Maxim Group LLC will return to us the amount previously advanced
by
us less Maxim Group LLC’s actual out-of-pocket expenses incurred in connection
with the offering.
We
estimate that the total expenses of the offering payable by us, not including
underwriting discounts, commissions, the non-accountable expense allowance
and
not taking into consideration the underwriters’ over-allotment option, will be
approximately $380,000. These expenses include, but are not limited to, SEC
registration fees, NASD filing fees, accounting fees and expenses, legal fees
and expenses, printing and engraving expenses, transfer agent fees and blue
sky
fees and expenses.
The
underwriters will initially offer the units to be sold in this offering directly
to the public at the initial public offering price set forth on the cover of
this prospectus and to selected dealers at the initial public offering price
less a selling concession not in excess of $ per unit. The underwriters may
allow, and the selected dealers may reallow, a concession not in excess of
$ per
unit on sales to brokers and dealers. After the offering, the underwriters
may
change the offering price and other selling terms. No change in those terms
will
change the amount of proceeds to be received by us as set forth on the cover
of
this prospectus.
We
have
agreed to sell to the representative, for $100, an option to purchase up to
a
total of 300,000 units, exercisable at $10.00 per unit. The warrants issued
in
conjunction with these units will be exercisable at $7.50 per share. Otherwise,
the units issuable upon exercise of this option are identical to those offered
by this prospectus. This option commences on the later of the consummation
of a
business combination and one year from the date of this prospectus and expiring
five years from the date of this prospectus. The option and the 300,000 units,
the 300,000 shares of common stock and the 300,000 warrants underlying such
units, and the 300,000 shares of common stock underlying such warrants, have
been deemed compensation by the NASD and are therefore subject to a 180-day
lock-up pursuant to Rule 2710(g)(1) of the NASD Conduct Rules. Additionally,
the
option may not be sold, transferred, assigned, pledged or hypothecated for
a
one-year period (including the foregoing 180-day period) following the date
of
this prospectus. However, the option may be transferred to any underwriter
and
selected dealer participating in the offering and their bona fide officers
or
partners. Thereafter, the representative’s units will be transferable provided
such transfer is in accordance with the provisions of the Securities Act.
Although the purchase option and its underlying securities have been registered
under the registration statement of which this prospectus forms a part of,
the
option grants to holders demand and “piggy back” rights for periods of five and
seven years, respectively, from the date of this prospectus with respect to
the
registration under the Securities Act of the securities directly and indirectly
issuable upon exercise of the option. We will bear all fees and expenses
attendant to registering the securities, other than underwriting commissions
which will be paid for by the holders themselves. The exercise price and number
of units issuable upon exercise of the option may be adjusted in certain
circumstances including in the event of a stock dividend, or our
recapitalization, reorganization, merger or consolidation. However, the option
will not be adjusted for issuances of common stock at a price below its exercise
price. We will set aside and at all times have available a sufficient number
of
shares of common stock to be issued upon exercise of the representative’s
units.
We
have
engaged Maxim Group LLC, the representative of the underwriters, on a
non-exclusive basis, as our agent for the solicitation of the exercise of the
warrants. To the extent not inconsistent with the guidelines of the NASD and
the
rules and regulations of the SEC, we have agreed to pay the representative
for
bona fide services rendered a commission equal to 4% of the exercise price
for
each warrant exercised more than one year after the date of this prospectus
if
the exercise was solicited by the underwriters. In addition to soliciting,
either orally or in writing, the exercise of the warrants, the representative’s
services may also include disseminating information, either orally or in
writing, to warrant holders about us or the market for our securities, and
assisting in the processing of the exercise of the warrants. No compensation
will be paid to the representative upon the exercise of the warrants if:
· |
the
market price of the underlying shares of common stock is lower than
the
exercise price;
|
· |
the
holder of the warrants has not confirmed in writing that the underwriters
solicited the exercise;
|
· |
the
warrants are held in a discretionary account;
|
· |
the
warrants are exercised in an unsolicited transaction; or
|
· |
the
arrangement to pay the commission is not disclosed in the prospectus
provided to warrant holders at the time of exercise.
|
Subject
to any regulatory restrictions, Maxim Group LLC, the representative of the
underwriters, or certain of its principals, affiliates or designees, has agreed
to purchase up to $500,000 of our warrants on the open market, at prices per
warrant not to exceed $1.20, within three months of such warrants being
separately tradeable.
Prior
to
this offering there has been no public market for any of our securities. The
public offering price of the units and the terms of the warrants were negotiated
between us and the representative. Factors considered in determining the prices
and terms of the units, including the common stock and warrants underlying
the
units, include:
· |
the
history and prospects of companies whose principal business is the
acquisition of other companies;
|
· |
prior
offerings of those companies;
|
· |
our
prospects for acquiring an operating business at attractive values;
|
· |
an
assessment of our management and their experience in identifying
operating
companies;
|
· |
general
conditions of the securities markets at the time of the offering;
and
|
· |
other
factors as were deemed relevant.
|
However,
although these factors were considered, the determination of our offering price
is more arbitrary than the pricing of securities for an operating company in
a
particular industry since the underwriters are unable to compare our financial
results and prospects with those of public companies operating in the same
industry.
Although
they are not obligated to do so, any of the underwriters may introduce us to
potential target businesses or assist us in raising additional capital, as
needs
may arise in the future, but there are no preliminary agreements or
understandings between any of the underwriters and any potential targets. We
are
not under any contractual obligation to engage any of the underwriters to
provide any services for us after this offering, but if we do, we may pay the
underwriters a finder’s fee that would be determined at that time in an arm’s
length negotiation where the terms would be fair and reasonable to each of
the
interested parties; provided that no agreement will be entered into and no
fee
will be paid prior to the one year anniversary of the date of this prospectus.
In
connection with this offering, the underwriters may distribute prospectuses
electronically. No forms of prospectus other than printed prospectuses and
electronically distributed prospectuses that are printable in Adobe PDF format
will be used in connection with this offering.
The
underwriters have informed us that they do not expect to confirm sales of units
offered by this prospectus to accounts over which they exercise discretionary
authority without obtaining the specific approval of the account
holder.
In
connection with this offering, our underwriters may engage in stabilizing
transactions, over-allotment transactions, covering transactions and penalty
bids in accordance with Regulation M under the Securities Exchange Act of 1934,
as amended.
· |
Stabilizing
transactions permit bids to purchase the underlying security so long
as
the stabilizing bids do not exceed a specified
maximum.
|
· |
Over-allotment
involves sales by the underwriters of units in excess of the number
of
units the underwriters are obligated to purchase, which creates a
short
position. The short position may be either a covered short position
or a
naked short position. In a covered short position, the number of
units
over-allotted by the underwriters is not greater than the number
of units
that it may purchase in the over-allotment option. In a naked short
position, the number of units involved is greater than the number
of units
in the over-allotment option. The underwriters may close out any
covered
short position by either exercising their over-allotment option or
purchasing units in the open
market.
|
· |
Covering
transactions involve the purchase of units in the open market after
the
distribution has been completed in order to cover short positions.
In
determining the source of units to close out the short position,
the
underwriters will consider, among other things, the price of units
available for purchase in the open market as compared to the price
at
which it may purchase units through the over-allotment option. If
the
underwriters sell more units than could be covered by the over-allotment
option, a naked short position, the position can only be closed out
by
buying units in the open market. A naked short position is more likely
to
be created if the underwriters are concerned that there could be
downward
pressure on the price of the units in the open market after pricing
that
could adversely affect investors who purchase in this
offering.
|
· |
Penalty
bids permit the underwriters to reclaim a selling concession from
a
selected dealer when the units originally sold by the selected dealer
is
purchased in a stabilizing covering transaction to cover short
positions.
|
These
stabilizing transactions, covering transactions and penalty bids may have the
effect of raising or maintaining the market price of our units or preventing
or
retarding a decline in the market price of our units. As a result, the price
of
our units may be higher than the price that might otherwise exist in the open
market. However, neither we nor the underwriters make any representation or
prediction as to the effect the transactions described above may have on the
price of our securities. These
transactions may occur on the OTC Bulletin Board, in the over-the-counter market
or on any trading market. If any of these transactions are commenced, they
may
be discontinued without notice at any time.
Although
certain principals of Maxim Group LLC have extensive experience in the
securities industry, Maxim Group LLC itself was formed in October 2002 and
has
acted as an underwriter in only two firm commitment public offerings, co-manager
in two firm commitment public offerings and as a member of the underwriting
syndicate in forty underwritten public offerings. Since Maxim Group LLC has
limited experience in underwriting firm commitment public offerings, their
lack
of experience may adversely affect the public offering price of our securities
and the subsequent development, if any, of a trading market for our securities.
Maxim Group LLC is a member of the National Association of Securities Dealers,
Inc. and the Securities Investor Protection Corporation.
The
underwriting agreement provides for indemnification between us and the
underwriters against specified liabilities, including liabilities under the
Securities Act, and for contribution by us and the underwriters to payments
that
may be required to be made with respect to those liabilities. We have been
advised that, in the opinion of the Securities and Exchange Commission,
indemnification liabilities under the Securities Act is against public policy
as
expressed in the Securities Act, and is therefore, unenforceable.
The
validity of the securities offered in this prospectus is being passed upon
for
us by Ellenoff Grossman & Schole LLP, New York, New York. Such firm has
previously represented Maxim Group LLC and expects to do so again in the future.
Lowenstein Sandler PC is acting as counsel for the underwriters in this
offering.
The
financial statements included in this prospectus and in the registration
statement have been audited by LWBJ, LLP, an independent registered public
accounting firm, to the extent and for the period set forth in their report
appearing elsewhere in this prospectus and in the registration statement. The
financial statements and the report of LWBJ, LLP are included in reliance upon
their report given upon the authority of LWBJ, LLP as experts in auditing and
accounting.
We
have
filed with the SEC a registration statement on Form S-1, which includes
exhibits, schedules and amendments, under the Securities Act, with respect
to
this offering of our securities. Although this prospectus, which forms a part
of
the registration statement, contains all material information included in the
registration statement, parts of the registration statement have been omitted
as
permitted by rules and regulations of the SEC. We refer you to the registration
statement and its exhibits for further information about us, our securities
and
this offering. The registration statement and its exhibits, as well as our
other
reports filed with the SEC, can be inspected and copied at the SEC’s public
reference room at 450 Fifth Street, N.W., Washington, D.C. 20549-1004.
The
public may obtain information about the operation of the public reference room
by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains a web
site
at http://www.sec.gov which contains the Form S-1 and other reports,
proxy
and information statements and information regarding issuers that file
electronically with the SEC.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Financial
Statements
April
30,
2005
Contents
Report
of Independent Auditors
|
F-1
|
|
|
Audited
Financial Statements
|
|
|
|
Balance
Sheet
|
F-2
|
Statement
of Operations
|
F-3
|
Statement
of Stockholders' Equity
|
F-4
|
Statement
of Cash Flows
|
F-5
|
Notes
to Financial Statements
|
F-6
- F-10
|
Report
of Independent Auditors
The
Board
of Directors
Healthcare
Acquisition Corp.
We
have
audited the accompanying balance sheet of Healthcare Acquisition Corp.
(a
corporation in the development stage) as of April 30, 2005, and the related
statements of operations, stockholders' equity, and cash flows for the
period
from April 25, 2005 (inception) to April 30, 2005. These financial statements
are the responsibility of the Company's management. Our responsibility
is to
express an opinion on these financial statements based on our audit.
We
conducted our audit in accordance with auditing standards of the Public
Company
Accounting Oversight Board (United States). Those standards require that
we plan
and perform the audit to obtain reasonable assurance about whether the
financial
statements are free of material misstatement. The Company is not required
to
have, nor were we engaged to perform, an audit of its internal control
over
financial reporting. Our audit included consideration of internal control
over
financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing
an
opinion on the effectiveness of the Company's internal control over financial
reporting. Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and disclosures
in
the financial statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.
In
our
opinion, the financial statements referred to above present fairly, in
all
material respects, the financial position of Healthcare Acquisition Corp.
(a
corporation in the development stage) as of April 30, 2005, and the results
of
its operations and its cash flows for the period from April 25, 2005 (inception)
to April 30, 2005, in conformity with accounting principles generally accepted
in the United States of America.
/s/
LWBJ,
LLP
West
Des
Moines, Iowa
May
6,
2005
HEALTHCARE
ACQUISITION CORP.
|
(a
corporation in the development
stage)
|
|
Balance
Sheet
|
|
April
30, 2005
|
|
|
|
|
Assets
|
|
|
|
Current
assets:
|
|
|
|
Cash
|
|
$
|
140,000
|
|
|
|
|
|
|
Other
assets:
|
|
|
|
|
Deferred
offering costs
|
|
|
113,253
|
|
Total
assets
|
|
$
|
253,253
|
|
|
|
|
|
|
Liabilities
and stockholders' equity
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
Accrued
expenses
|
|
$
|
55,753
|
|
Notes
payable, stockholders
|
|
|
175,000
|
|
Total
current liabilities
|
|
|
230,753
|
|
|
|
|
|
|
Stockholders'
equity:
|
|
|
|
|
Preferred
stock, $.0001par value, 1,000,000 shares authorized; none
issued
|
|
|
|
|
Common
stock, $.0001 par value, 100,000,000 shares authorized; 1,500,000
issued and outstanding
|
|
|
150
|
|
Additional
paid-in capital
|
|
|
24,850
|
|
Deficit
accumulated during the development stage
|
|
|
(2,500
|
)
|
Total
stockholders' equity
|
|
|
22,500
|
|
Total
liabilities and stockholders' equity
|
|
$
|
253,253
|
|
|
|
|
|
|
|
|
|
|
|
See
accompanying notes.
|
|
|
|
|
HEALTHCARE
ACQUISITION CORP.
|
(a
corporation in the development
stage)
|
|
Statement
of Operations
|
|
For
the period from April 25, 2005 (inception) to April 30,
2005
|
|
|
|
|
|
|
|
|
Formation
and operating costs
|
|
$
|
(2,500
|
) |
|
|
|
|
|
Net
loss
|
|
$
|
(2,500
|
) |
|
|
|
|
|
Weighted
average shares outstanding
|
|
|
1,500,000
|
|
|
|
|
|
|
Net
loss per share
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
See
accompanying notes.
|
|
|
|
|
HEALTHCARE
ACQUISITION
CORP.
|
(a
corporation in the development
stage)
|
|
Statement
of Stockholders'
Equity
|
|
For
the period from April 25, 2005 (inception) to April 30,
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
Deficit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paid-in
|
|
|
Accumulated
|
|
|
|
|
|
|
|
Common
Stock
|
|
|
Capital
in
|
|
|
During
the
|
|
|
Stockholders'
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Excess
of Par
|
|
|
Development
Stage
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
shares issued
|
|
|
1,500,000
|
|
$
|
150
|
|
$
|
24,850
|
|
$
|
-
|
|
$
|
25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(2,500
|
)
|
|
(2,500
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at April 30, 2005
|
|
|
1,500,000
|
|
$
|
150
|
|
$
|
24,850
|
|
$
|
(2,500
|
)
|
$
|
22,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See
accompanying notes.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HEALTHCARE
ACQUISITION CORP.
|
(a
corporation in the development
stage)
|
|
Statement
of Cash Flows
|
|
For
the period from April 25, 2005 (inception) to April 30,
2005
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
|
|
Net
loss
|
|
$
|
(2,500
|
)
|
Net
cash used in operating activities
|
|
|
(2,500
|
)
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
Proceeds
from note payable, stockholders
|
|
|
175,000
|
|
Proceeds
from sale of common stock
|
|
|
25,000
|
|
Payments
made for deferred offering costs
|
|
|
(57,500
|
)
|
Net
cash provided by financing activities
|
|
|
142,500
|
|
Net
increase in cash
|
|
|
140,000
|
|
|
|
|
|
|
Cash
at beginning of period
|
|
|
-
|
|
Cash
at end of period
|
|
$
|
140,000
|
|
|
|
|
|
|
Supplemental
schedule of non-cash financing activities
|
|
|
|
|
Accrual
of deferred offering costs
|
|
$
|
55,573
|
|
|
|
|
|
|
|
|
|
|
|
See
accompanying notes.
|
|
|
|
|
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements
April
30,
2005
1. Nature
of Operations and Summary of Significant Accounting
Policies
Nature
of Operations
Healthcare
Acquisition Corp. (the "Company") was incorporated in Delaware on April
25,
2005, as a blank check company whose objective is to acquire, through
a merger,
capital stock exchange, asset acquisition or other similar business combination,
a currently unidentified operating business.
At
April
30, 2005, the Company had not yet commenced any operations. All activity
through
April 30, 2005 relates to the Company's formation and the proposed public
offering described below. The Company has selected December 31 as its
fiscal
year-end. The Company's ability to commence operations is contingent
upon
obtaining adequate financial resources through a proposed public offering
("Proposed Offering"), which is discussed in Note 2. The Company's management
has broad discretion with respect to the specific application of the
net
proceeds of this Proposed Offering, although substantially all of the
net
proceeds of the Proposed Offering are intended to be generally applied
toward
consummating a business combination with an operating domestic or international
company in the healthcare industry, a "target business".
In
evaluating a prospective target business, the Company will consider,
among other
factors, the financial condition and results of operation; growth potential;
experience and skill of management; availability of additional personnel;
capital requirements; competitive position; barriers to entry into other
industries; stage of development of the products, processes or services;
degree
of current or potential market acceptance of the products, processes
or
services; proprietary features and degree of intellectual property or
other
protection of the products, processes or services; regulatory environment
of the
industry; and costs associated with effecting the business combination.
These
criteria are not intended to be exhaustive. Any evaluation relating to
the
merits of a particular business combination will be based, to the extent
relevant, on the above factors, as well as other considerations deemed
relevant
by the Company in effecting a business combination consistent with its
business
objective.
Upon
the
closing of the Proposed Offering, $42,960,000 or 89.5% of the proceeds
of this
offering ($7.16 per unit) will be placed in a trust account at JP Morgan
Chase
NY Bank maintained by Continental Stock Transfer & Trust Company ("Trust
Fund") and invested in United States Treasury Bills having a maturity
of one
hundred eighty (180) days or less, until the earlier of (i) the consummation
of
the Company's first business combination or (ii) the liquidation of the
Company.
The remaining proceeds, not held in trust, may be used to pay for business,
legal and accounting expenses related to this offering or expenses which
may be
incurred related to the investigation and selection of a target business,
and
the negotiation of an agreement to acquire a target business.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
1. Nature
of Operations and Summary of Significant Accounting Policies
(continued)
Nature
of Operations (continued)
The
Company's first business combination must be with a business with a fair
market
value of at least 80% of the Company's net asset value at the time of
acquisition. The Company, after signing a definitive agreement for the
acquisition of a target business, will submit such transaction for stockholder
approval. In the event that stockholders owning 20% or more of the outstanding
stock excluding, for this purpose, those persons who were stockholders
prior to
the Proposed Offering, vote against the business combination and
request
their consummation right as described below, the business combination
will not
be consummated. All of the Company's stockholders prior to the Proposed
Offering, including all of the officers and directors of the Company
("Initial
Stockholders"), have agreed to vote their 1,500,000 founding shares of
common
stock in accordance with the vote of the majority in interest of all
other
stockholders of the Company ("Public Stockholders") with respect to any
business
combination. After consummation of the Company's first business combination,
all
of these voting safeguards will no longer be applicable.
With
respect to the first business combination which is approved and consummated,
any
Public Stockholder who voted against the business combination may demand
that
the Company redeem his or her shares. The per share redemption price
will equal
the amount in the Trust Fund as of the record date for determination
of
stockholders entitled to vote on the business combination divided by
the number
of shares of common stock held by Public Stockholders at the consummation
of the
Proposed Offering. Accordingly, Public Stockholders holding 19.99% of
the
aggregate number of shares owned by all Public Stockholders may seek
redemption
of their shares in the event of a business combination. Such Public Stockholders
are entitled to receive their per share interest in the Trust Fund computed,
without regard to the shares held by Initial Stockholders.
The
Company's Restated Certificate of Incorporation provides for mandatory
liquidation of the Company, without stockholder approval, in the event
that the
Company does not consummate a business combination within eighteen (18)
months
from the date of the consummation of the Proposed Offering, or twenty-four
(24)
months from the consummation of the Proposed Offering if certain extension
criteria have been satisfied. In the event of liquidation, it is likely
that the
per share value of the residual assets remaining available for distribution
(including Trust Fund assets) will be less than the initial public offering
price per share in the Proposed Offering (assuming no value is attributed
to the
Warrants contained in the Units to be offered in the Proposed Offering
discussed
in Note 2.)
The
Company's common stock and Warrants will not be traded separately until
it files
an audited balance sheet on Form 8-K with the Securities and Exchange
Commission, which reflects receipt of the gross proceeds from the Proposed
Offering. Upon completion of the Proposed Offering, shares owned by the
Initial
Stockholders will be held in an escrow account maintained by the trustee,
acting
as escrow agent, for up to three (3) years.
Loss
Per Common Share
Loss
per
share is computed by dividing net loss by the weighted-average number
of shares
of common stock outstanding during the period.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
1. Nature
of Operations and Summary of Significant Accounting Policies
(continued)
Use
of Estimates
The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management
to make
estimates and assumptions that affect the reported amounts of assets
and
liabilities at the date of the financial statements and the reported
amounts of
expenses during the reporting period. Actual results could differ from
those
estimates.
Income
Taxes
Deferred
income taxes are provided for the differences between the basis of assets
and
liabilities for financial reporting and income tax purposes. A valuation
allowance is established, when necessary, to reduce deferred tax assets
to the
amount expected to be realized.
The
Company recorded a deferred income tax asset for the tax effect of net
operating
loss carryforwards and temporary differences aggregating to approximately
$1,000. In recognition of the uncertainty regarding the ultimate amount
of
income tax benefits to be derived, the Company has recorded a full valuation
allowance at April 30, 2005.
The
effective tax rate differs from the statutory rate of 34% due to the
increase in
the valuation allowance.
Recent
Accounting Pronouncements
The
Company does not believe that any recently issued, but not yet effective,
accounting standards, if currently adopted, would have a material effect
on the
accompanying financial statements.
2. Proposed
Public Offering
The
Proposed Offering calls for the Company to offer for public sale up to
6,000,000
units ("Units") at a maximum price of $8.00 per unit. Each Unit consists
of one
share of the Company's common stock, $.0001 par value and one Redeemable
Common
Stock Purchase Warrant ("Warrant"). Each Warrant will entitle the holder
to
purchase from the Company one share of common stock at an exercise price
of
$6.00 commencing the later of the completion of a business combination
with a
target business or one (1) year from the effective date of the Proposed
Offering
and expiring four (4) years from the date of the prospectus. An additional
900,000 Units may be issued on exercise of a 45-day option granted to
the
underwriters to cover any over-allotments. The Warrants will be redeemable
by
the Company, upon prior written consent of the underwriters, at a price
of $.01
per Warrant, upon thirty (30) days notice after the Warrants become exercisable,
only in the event that the average sales price of the common stock is
at least
$11.50 per share for any twenty (20) trading days within a thirty (30)
trading-day period ending on the third day prior to date on which notice
of
redemption is given.
3. Deferred
Offering Costs
Deferred
offering costs consist principally of underwriting fees, legal fees,
accounting
fees, and other fees incurred through the balance sheet date that are
related to
the Proposed Offering and that will be charged to capital upon the receipt
of
the capital raised.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
4. Notes
Payable, Stockholders
The
Company issued an aggregate of $175,000 unsecured promissory notes to
three
Initial Stockholders, who are also officers, on April 28, 2005. The notes
are
non-interest bearing and are payable on the earlier of April 28, 2006
or the
consummation of the Proposed Offering. Due to the short-term nature of
the
notes, the fair value of the notes approximates their carrying
amount.
5. Commitments
and Contingencies
The
Company has agreed to pay up to $7,500 per month, beginning at the effective
date of the Proposed Offering, for office space and general and administrative
expense to two (2) related entities owned by two (2) of the Initial Stockholders
located in Des Moines, Iowa and Rochester, New York. The remaining Initial
Stockholder is an officer of one of the related entities. Upon completion
of a
business combination or liquidation, the Company will no longer be required
to
pay these monthly fees.
An
Initial Stockholder has agreed that after this offering is completed
and within
the first ninety (90) days after separate trading of the Warrants has
commenced,
he or certain designees will collectively purchase up to $1,000,000 of
the
Company's Warrants in the public marketplace at prices not to exceed
$1.20 per
Warrant. He has further agreed that any Warrants purchased by him or
his
affiliates or designees, will not be sold or transferred until the completion
of
a business combination. In addition, subject to any regulatory
restrictions and within the first ninety (90) days after separate
trading
of the Warrants has commenced, the representative of the underwriters,
or
certain of its principals, affiliates or designees has agreed to purchase
up to
$500,000 of the Company's Warrants in the public marketplace at prices
not to
exceed $1.20 per Warrant.
The
Company has agreed to sell to the representative of the underwriters
for $100,
an option to purchase up to a total of 300,000 units. The units issuable
upon
exercise of this option are identical to those offered by the prospectus,
except
that the warrants included in the option have an exercise price of $7.50
(125%
of the exercise price of the warrants included in the Units sold in the
offering). This option is exercisable at $10.00 per unit commencing on
the later
of the consummation of a business combination and one (1) year from the
date of
the prospectus and expiring five (5) years from the date of the prospectus.
The
option and the 300,000 units, the 300,000 shares of common stock and
the
warrants underlying such units, and the shares of common stock underlying
such
Warrants, may be deemed compensation by the National Association of Securities
Dealers ("NASD") and may be therefore subject to a 180-day lock-up pursuant
to
Rule 2710(g)(1) of the NASD Conduct Rules. Additionally, the option may
not be
sold, transferred, assigned, pledged or hypothecated for a one-year period
(including the foregoing 180-day period) following the date of the prospectus.
However, the option may be transferred to any underwriter and selected
dealer
participating in the offering and their bona fide officers or partners.
Although
the purchase option and its underlying securities have been registered
under the
registration statement of which the prospectus forms a part of, the option
grants to holders demand and "piggy back" rights for periods of five
(5) and
seven (7) years, respectively, from the date of the prospectus with respect
to
the registration under the Securities Act of the securities directly
and
indirectly issuable upon exercise of the option. The Company will bear
all fees
and expenses attendant to registering the securities, other than underwriting
commissions, which will be paid for by the holders themselves. The exercise
price and number of units issuable upon exercise of the option may be
adjusted
in certain circumstances, including in the event of a stock dividend,
or our
recapitalization, reorganization, merger or consolidation. However, the
option
will not be adjusted for issuances of common stock at a price below its
exercise
price.
HEALTHCARE
ACQUISITION CORP.
(a
corporation in the development stage)
Notes
to
Financial Statements (continued)
5. Commitments
and
Contingencies (continued)
The
Company has engaged a third party to act as the representative of the
underwriters, on a non-exclusive basis, as its agent for the solicitation
of the
exercise of the Warrants. To the extent not inconsistent with the guidelines
of
the NASD and the rules and regulations of the Securities and Exchange
Commission, the Company has agreed to pay the representative for bona
fide
services rendered, a commission equal to 4% of the exercise price for
each
Warrant exercised more than one (1) year after the date of this prospectus
if
the exercise was solicited by the underwriters. In addition to soliciting,
either orally or in writing, the exercise of the Warrants, the representative's
services may also include disseminating information, either orally or
in
writing, to Warrant holders about the Company or the market for its securities,
and assisting in the processing of the exercise of the Warrants. No compensation
will be paid to the representative upon the exercise of the Warrants
if:
· |
the
market price of the underlying shares of common stock is lower
than the
exercise price;
|
· |
the
holder of the Warrants has not confirmed in writing that the
underwriters
solicited the exercise;
|
· |
the
Warrants are held in a discretionary
account;
|
· |
the
Warrants are exercised in an unsolicited transaction;
or
|
· |
the
arrangement to pay the commission is not disclosed in the prospectus
provided to Warrant holders at the time of
exercise.
|
Upon
consummation of a business combination, the Company is obligated to pay
the
underwriters an additional underwriting discount of $480,000.
The
Initial Stockholders who are holders of 1,500,000 issued and outstanding
shares
of common stock will be entitled to registration rights pursuant to an
agreement
to be signed prior to or on the effective date of this Proposed Offering.
The
holders of the majority of these shares are entitled to request the Company,
on
up to two (2) occasions, to register these shares. The holders of the
majority
of these shares can elect to exercise these registration rights at any
time
after the date on which these shares of common stock are released from
escrow.
In addition, these stockholders have certain "piggy-back" registration
rights on
registration statements filed subsequent to the date on which these shares
of
common stock are released from escrow. The Company will bear the expenses
incurred in connection with the filing of any such registration
statements.
The
Company is authorized to issue 1,000,000 shares of preferred stock with
such
designations, voting and other rights and preferences, as may be determined
from
time to time by the Board of Directors.
|
|
Until
[
],
2005, all dealers that effect transactions in these securities, whether
or
not participating in this offering, may be required to deliver a
prospectus. This is in addition to the dealers’ obligation to deliver a
prospectus when acting as underwriters and with respect to their
unsold
allotments or subscriptions.
No
dealer, salesperson or any other person is authorized to give any
information or make any representations in connection with this offering
other than those contained in this prospectus and, if given or made,
the
information or representations must not be relied upon as having
been
authorized by us. This prospectus does not constitute an offer to
sell or
a solicitation of an offer to buy any security other than the securities
offered by this prospectus, or an offer to sell or a solicitation
of an
offer to buy any securities by anyone in any jurisdiction in which
the
offer or solicitation is not authorized or is unlawful.
|
$48,000,000
[LOGO]
HEALTHCARE
ACQUISITION CORP.
6,000,000
Units
________________
PROSPECTUS ________________
Maxim
Group LLC
________,
2005
|
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
13. Other Expenses of Issuance and Distribution.
The
estimated expenses payable by us in connection with the offering described
in
this registration statement (other than the underwriting discount and
commissions and the representative’s non-accountable expense allowance) will be
as follows:
Initial
Trustees’ fee
|
|
$
|
1,000.00
|
|
|
(1
|
)
|
SEC
Registration Fee
|
|
|
11,988.00
|
|
|
|
|
NASD
filing fee
|
|
|
10,685.00
|
|
|
|
|
Accounting
fees and expenses
|
|
|
25,000.00
|
|
|
|
|
Printing
and engraving expenses
|
|
|
50,000.00
|
|
|
|
|
Directors
& Officers liability insurance premiums
|
|
|
70,000.00
|
|
|
(2
|
)
|
Legal
fees and expenses
|
|
|
150,000.00
|
|
|
|
|
Blue
sky services and expenses
|
|
|
50,000.00
|
|
|
|
|
Miscellaneous
|
|
|
11,327.00
|
|
|
(3
|
)
|
Total
|
|
$
|
380,000.00
|
|
|
|
|
(1) In
addition to the initial acceptance fee that is charged by Continental Stock
Transfer & Trust Company, as trustee following the offering, the
registrant will be required to pay to Continental Stock Transfer &
Trust Company annual fees of approximately $3,000 for acting as trustee,
approximately $4,800 for acting as transfer agent of the registrant’s common
stock, approximately $2,400 for acting as warrant agent for the registrant’s
warrants and approximately $1,800 for acting as escrow agent.
(2) This
amount represents the approximate amount of Director and Officer liability
insurance premiums that we anticipate paying following the consummation of
our
initial public offering and until we consummate a business combination.
(3) This
amount represents additional expenses that may be incurred by us in connection
with the offering over and above those specifically listed above, including
distribution and mailing costs.
Our
certificate of incorporation provides that all of our directors, officers,
employees and agents shall be entitled to be indemnified by us to the fullest
extent permitted by Section 145 of the Delaware General Corporation
Law.
Section 145
of the Delaware General Corporation Law concerning indemnification of officers,
directors, employees and agents is set forth below.
“Section 145. Indemnification
of officers, directors, employees and agents; insurance.
(a) A
corporation shall have power to indemnify any person who was or is a party
or is
threatened to be made a party to any threatened, pending or completed action,
suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the corporation) by reason of the
fact that the person is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses (including attorneys’
fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by the person in connection with such action, suit or proceeding if
the
person acted in good faith and in a manner the person reasonably believed to
be
in or not opposed to the best interests of the corporation, and, with respect
to
any criminal action or proceeding, had no reasonable cause to believe the
person’s conduct was unlawful. The termination of any action, suit or proceeding
by judgment, order, settlement, conviction, or upon a plea of nolo contendere
or
its equivalent, shall not, of
itself, create a presumption that the person did not act in good faith and
in a
manner which the person reasonably believed to be in or not opposed to the
best
interests of the corporation, and, with respect to any criminal action or
proceeding, had reasonable cause to believe that the person’s conduct was
unlawful.
(b) A
corporation shall have power to indemnify any person who was or is a party
or is
threatened to be made a party to any threatened, pending or completed action
or
suit by or in the right of the corporation to procure a judgment in its favor
by
reason of the fact that the person is or was a director, officer, employee
or
agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise against expenses (including attorneys’
fees) actually and reasonably incurred by the person in connection with the
defense or settlement of such action or suit if the person acted in good faith
and in a manner the person reasonably believed to be in or not opposed to the
best interests of the corporation and except that no indemnification shall
be
made in respect of any claim, issue or matter as to which such person shall
have
been adjudged to be liable to the corporation unless and only to the extent
that
the Court of Chancery or the court in which such action or suit was brought
shall determine upon application that, despite the adjudication of liability
but
in view of all the circumstances of the case, such person is fairly and
reasonably entitled to indemnity for such expenses which the Court of Chancery
or such other court shall deem proper.
(c) To
the
extent that a present or former director or officer of a corporation has been
successful on the merits or otherwise in defense of any action, suit or
proceeding referred to in subsections (a) and (b) of this section,
or
in defense of any claim, issue or matter therein, such person shall be
indemnified against expenses (including attorneys’ fees) actually and reasonably
incurred by such person in connection therewith.